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ATK arachidonyl trifluoromethylketone
BEL bromoenol lactone
4-BPB 4-bromophenacyl bromide
CaLB calcium-dependent phospholipid binding
Cdk cyclin-dependent kinase
CHO chinese hamster ovary
COX cyclooxygenase
DAG dipalmitoylglycerol
DMEM Dulbeccos modified Eagles medium
DNA deoxyribonucleic acid
DTT 1,4-dithiothreitol
E2F E2 promoter binding factor
EGF epidermal growth factor
EGTA ethyleneglycol-bis(β-aminoethyl)-N,N,N,N-tetraacetic acid
ERK extracellular regulated kinase
FBS foetal bovine serum
FGF fibroblast growth factor
Gö6976 12-(2-cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo
[2,3-a]pyrrolo[3,4-c]carbazole
Gö6983 2-[1-(3-diamethylaminopropyl)-5-methoxyindol-3-yl]-3-(1H-indol-3-yl)maleimide
Grb2 growth factor receptor binding protein 2
H2O2 hydrogen peroxide
INK4 inhibitors of cdk4
IP3 inositol 1,4,5-trisphosphate
JNK/SAPK c-jun NH2-terminal kinase/ stress-activated protein kinase
kDa kilo dalton
LO lipoxygenase
LY294002 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
MAPK mitogen-activated protein kinase
MEK MAPK kinase or ERK kinase
Mnk1 MAP kinase interaction protein kinase 1
N2A neuroblastoma 2A
NDGA nordihydroguaiaretic acid
NS-398 N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide
PBS phosphate buffered saline
PD098059 2-(2-amino-3methoxyphenyl)-oxanaphtalen-4-one
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PdBu phorbol-12,13-dibutyrate
PDGF platelet-derived growth factor
PGHS prostaglandin H synthase
PI3K phosphatidylinositol 3-kinase
PIP2 phosphatidylinositol-4,5-bisphosphate
PKC protein kinase C
cPLA2 cytosolic phospholipase A2
iPLA2 calcium-independent phospholipase A2
sPLA2 secretory phospholipase A2
PLCγ phosphoinositide-specific phospholipase Cγ
PMSF phenylmethylsulfonyl fluoride
Rb retinoblastoma
Ro31-8220 3-[1-[3(amidinothio)propyl-1H-indol-3-yl]-3-(1-methyl-1H-indol-3-yl)maleimide
ROS reactive oxygen species
SDS-PAGE sodium dodecylsulfate-polyacrylamide gelelecrophoresis
Sos son of sevenless
U0126 [1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene]
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Introduction
Phospholipases A2 are enzymes that hydrolyse fatty acids from the sn-2 position of
phospholipids, resulting in the release of free fatty acids and lysophospholipids (van den
Bosch, 1980; Dennis, 1997). The phospholipase A2 (PLA2) superfamily consists of a broad
range of enzymes amongst which are the secretory PLA2s (sPLA2; groups I, II, III, V, IX
and X), the Ca2+-independent PLA2 (iPLA2; group VI) and the cytosolic PLA2 (cPLA2;
group IV) (reviewed in Six & Dennis, 2000). The sn-2 position of phospholipids in
mammalian cells is enriched with arachidonic acid, which is a substrate for
cyclooxygenases, lipoxygenases and cytochrome p450s, giving PLA2s an important role in
the control of the synthesis of prostaglandins, leukotrienes and other eicosanoids. In
addition, PLA2s determine most of the arachidonic acid released in the cell. Arachidonic
acid and its metabolites, the eicosanoids, have been implicated in a number of physiological
and pathophysiologial processes, including the control of voltage-dependent and Ca2+
channels (Keyser & Alger, 1990; Peppelenbosch et al., 1992), modulation and release of
neurotransmitters (Lynch et al., 1989), blood vessel tone (Capdevila et al., 2000),
inflammation (Heller et al., 1998), mitogenic signalling (Korystov Yu et al., 1998) and
cancers (Shappell et al., 2001). Because arachidonic acid is preferentially released by
cPLA2, the understanding of its regulation is of great importance.
General aspects of cPLA2
Structure of cPLA2.
The cDNA for human cPLA2 was first cloned by Clark et al. and Sharp et al. in
1991. The sequence encodes a 85 kDa protein consisting of 749 amino acids which migrates
as a 100-110 kDa protein on SDS-PAGE. Within this sequence several domains and motifs
have been distinguished (fig. 1). At the N-terminus, a calcium-dependent lipid binding
(CaLB) domain is present (Clark, et al., 1991; Nalefski et al., 1994) which serves to bring
cPLA2 to the phospholipid substrate. This domain shares homology with the C2 domains
first identified in the conventional isoforms of protein kinase C (PKC) (Coussens et al.,
1986) and is found in a range of proteins including PLCγ and synaptotagmin (Clark et al.,
1995). The CaLB domain, spanning from amino acid 18-141 preferentially binds, unlike
other characterised C2 domains, to vesicles comprised of phosphatidylcholine in response
to physiological (0.3-1 µM) concentrations of calcium (Nalefski et al., 1998). In contrast to
the full length cPLA2, which displays preferential hydrolysis of arachidonoyl-containing
phospholipid vesicles, the cPLA2 C2 domain did not show a preference for phospholipid
vesicles composed of saturated, unsaturated sn-2 fatty acyl chains or the carbonyl oxygens
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at the sn-1 or sn-2 linkage (Nalefski, et al., 1998). Therefore, the cPLA2 C2 domain was
suggested to primarily interact with the headgroup of phosphatidylcholine. The crystal
structure of this C2 domain (Perisic et al., 1998) revealed an anti-parallel β-sandwich
consisting of two four-stranded sheets and three connecting loops, CBR1, 2 and 3. cPLA2
binds two Ca2+-ions between the three loops (Essen et al., 1997) which is also coordinated
by four acidic amino acids (Nalefski & Falke, 1996). Both CBR1 and CBR3 have a
prominent cluster of hydrophobic residues and therefore display preferential binding to
phospholipids with hydrophobic features of the headgroup like phosphatidylcholine in
preference to phosphatidylserine, phosphatidylinositol or phosphatidic acid (Wijkander &
Sundler, 1991; Nalefski, et al., 1994; Nalefski and Falke, 1996). In a model for the
membrane interaction of the CaLB domain, the hydrophobic CBR3 inserts into the
membrane displacing at least two phospholipids, and CBR1 interacts with the hydrophobic
regions of the lipid headgroup. Electrostatic interactions between the lipid headgroup and
the β-sandwich are weakened by the basic residues of one strand. Binding of calcium
renders the surface positively charged whereupon it is directed towards the membrane. One
important difference in membrane binding of the cPLA2 C2 domain as compared to other
C2 domains like in conventional PKC and synaptotagmin is that hydrophobic interactions
prevail over electrostatic interactions (Davletov et al., 1998).
Furthermore, cPLA2 contains the sequence G-L-S
228-G-S that closely resembles
the lipase consensus motif G-X-S-X-G present in many serine esterases and neutral lipases.
Site directed mutagenesis of Ser228 to alanine, cysteine or threonine resulted in a complete
Catalytic domain A
0 749
human cPLA
2
α
pSer727pSer505 
pSer454
pSer437GLSGS
CaLB Catalytic domain B
10120
GASGS
human cPLA
2
β
0 541
GVSGS
human cPLA
2
γ
CCLAMGXXXSX
Figure 1. Schematic representation of the primary structure of cPLA2α, β and γ.
loss of activity while cPLA2 remained correctly folded, thus demonstrating the essence of
Ser228 for catalytic activity of cPLA2 (Sharp et al., 1994; Huang et al., 1996). Besides Ser
228,
also Arg200 and Asp549 were shown to be essential for cPLA2 activity (Pickard et al., 1996).
cPLA2 has 9 cysteine residues but is, unlike sPLA2 enzymes, stable in the presence of
reducing agents showing that these residues are not essential for catalytic activity (Li et al.,
1994; Sharp, et al., 1994). However, modification of Cys331 with sulfhydryl-modifying
reagents resulted in a loss of catalytic activity, suggesting that Cys331 is located at a sensitive
position near the active site (Li et al., 1996; Pickard, et al., 1996). 
In addition to PLA2 activity, cPLA2 exhibits also lysophospholipase and weak
transacylase activity in the presence of lyso-PC micelles (Leslie, 1991; Reynolds et al.,
1993; Hanel & Gelb, 1995). No physiological relevance has been ascribed to the
transacylase activity, however, lysophospholipase activity has been implicated to play a
function in cells to control in this way the levels of potentially cytotoxic lysophospholipids
(de Carvalho et al., 1995).
It has been shown that phosphatidylinositol-4,5-bisphosphate (PIP2) mediates the
binding of cPLA2 to lipid vesicles, thereby increasing its activity in vitro in a calcium-
independent manner (Leslie & Channon, 1990; Buckland & Wilton, 1997; Mosior et al.,
1998). At first, Mosior et al. proposed a putative pleckstrin homology (PH) domain in
cPLA2 since some similarity was observed with a portion of the PH domain of PLCδ1.
However, from the crystal structure of cPLA2 protein no clear PH domain was identified
(Dessen et al., 1999). Although, addition of PIP2 to resting cells, or inhibiting the synthesis
of PIP2 correlated with an increase or decrease respectively, of cPLA2 activity (Balsinde et
al., 2000). This suggests that cPLA2 can interact directly with PIP2, generating a binding site
for cPLA2 in PIP2 enriched microdomains to which cPLA2 might translocate upon cell
stimulation.
Very recently, investigators demonstrated that ceramide can bind cPLA2 directly
via its CaLB domain thereby targeting cPLA2 to its substrate (Huwiler et al., 2001). This
binding occurred in a calcium-dependent fashion and increased cPLA2 activity towards
ceramide-containing liposomes. Similar results were also observed in calcium ionophore-
and epinephrine-stimulated CHO-2B cells. Besides an activation of cPLA2 by ceramide, an
inhibition in enzyme activity was measured in liposomal substrates containing
sphingomyelin, which could subsequently be restored by addition of cholesterol or ceramide
(Klapisz et al., 2000). This is potentially of interest in view of the regulation and subcellular
localisation of cPLA2 since ceramide, sphingomyelin and cholesterol are present in rafts
and/or caveolea (Brown & London, 1998; Dobrowsky, 2000).
In addition, the human cPLA2 sequence contains several consensus
phosphorylation sites for both serine/threonine and tyrosine protein kinases (Sharp, et al.,
1991). In Sf9 cells expressing recombinant human cPLA2, four serine residues (Ser
437,
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Ser454, Ser505, Ser727) are phosphorylated upon stimulation with the calcium ionophore
A23187 and okadaic acid (de Carvalho et al., 1996), although only Ser505 and Ser727 are
conserved in cPLA2 in other species and have physiological relevance. Ser
505 is situated in
the sequence P-L-S-P which is a consensus mitogen-activated protein kinase (MAPK)
phosphorylation site (de Carvalho, et al., 1996), and Ser727 lies in a consensus sequence (R-
X-S) for basotrophic kinases, such as PKC or PKA.
cPLA2 isoforms.
Recently, two new isoforms of the 85 kDa cPLA2 have been cloned and
characterised which are denoted cPLA2β and cPLA2γ (fig. 1) (Underwood et al., 1998;
Pickard et al., 1999; Song et al., 1999), giving the name cPLA2α to the already known 85
kDa cPLA2. cPLA2β and cPLA2γ share an overall sequence identity with cPLA2α of about
30%. cPLA2β is a 114 kDa protein consisting of 1012 amino acids which is present in most
tissues at a low level but is strongly expressed in pancreas and cerebellum (Pickard, et al.,
1999), brain and liver (Song, et al., 1999). Both cPLA2β and cPLA2α have a calcium-
dependent lipid binding (CaLB) domain that is lacking in cPLA2γ. However, this protein
does contain two consensus motifs for lipid modification, a prenylation motif at the C-
terminus and a myristoylation site at the N-terminus by which it is bound to the membrane
(Underwood, et al., 1998). Because cPLA2γ lacks the CaLB domain, the protein is much
shorter, 61 kDa consisting of 541 amino acids. Its mRNA is predominantly expressed in
skeletal muscle and heart, suggesting a specific role for cPLA2γ in these tissues. It may well
code for the Ca2+-independent PLA2 that was reported to be highly active under hypoxic
conditions, such as ischemia (Hazen et al., 1991; McHowat & Creer, 1997). 
The residues at which cPLA2α can be phosphorylated (Lin et al., 1993; Nemenoff
et al., 1993; de Carvalho, et al., 1996) are situated in a region dividing the catalytic domain
into two subdomains, A and B. These domains are not conserved in either of the two new
isoforms, suggesting that these enzymes are regulated by other mechanisms. All three
enzymes share a homologous catalytic region which contains the lipase consensus sequence
GXSXG that is located at the N-terminus and the three essential amino acid residues needed
for catalytic activity (Sharp, et al., 1991; Pickard, et al., 1996). However, in a liposome
assay sn-2 cleavage was observed for cPLA2α but sn-1 cleavage was preferred by cPLA2β,
whereas cPLA2γ was able to cleave at both sites (Song, et al., 1999). Thus the three cPLA2
family members have different regiospecificity towards 1-palmitoyl-2-arachidonyl-PC as a
substrate, and they may also have different headgroup specificities.
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Regulation of cPLA2 activity
Transcriptional and translational regulation.
cPLA2 is constitutively expressed in most cell types, however, extracellular stimuli,
such as interleukin-1, tumor necrosis factor-α (TNF-α), monocyte colony-stimulating factor
and epidermal growth factor (EGF) have been shown to induce the prolonged protein
expression of cPLA2 in various cell lines (Nakamura et al., 1992; Schalkwijk et al., 1993;
Chepenik et al., 1994), although these increases in expression levels are not as large a those
for sPLA2 group II. This is probably due to the gene structure of cPLA2 which has features
typical of a housekeeping gene (Kramer & Sharp, 1997). The increase in cPLA2 protein
expression is a result of enhancing translation of cPLA2 mRNA or by prolonging the half-
life of cPLA2 protein through mRNA stabilisation. Suppression of cPLA2 expression is
mediated by glucocorticoids, like dexamethasone (Hoeck et al., 1993; Schalkwijk, et al.,
1993). Interestingly, the fact that cPLA2 is constitutively expressed may render cPLA2 to be
capable of responding rapidly to physiological stimuli, whereas the prolonged increase in
cPLA2 protein and activity might be involved in developmental and differentiation
processes.
Post-translational regulation of cPLA2 activity.
cPLA2 requires calcium for its activity to translocate from the cytosol to the
membrane, where its substrate is located. This has been demonstrated in cells stimulated
with extracellular agents that mobilise calcium, including EGF and calcium ionophore
A23187, by both cell fractionation or microscopical approaches (Peters-Golden & McNish,
1993; Clark, et al., 1995; Glover et al., 1995; Schalkwijk et al., 1995). The translocation
from the cytosol to the membrane is mediated by the CaLB domain that binds two Ca2+-
ions. However, the calcium is not directly involved in catalysis (Nalefski, et al., 1994). This
is further supported by the observation that a cPLA2 mutant lacking the CaLB domain fails
to bind membranes while it is still catalytically active towards monomeric phospholipid
substrates.
In addition, a wide variety of agents have been shown to increase cPLA2
phosphorylation and activity (Clark, et al., 1995). The increase in cPLA2 activity is quite
modest, about 2-3-fold in agonist-stimulated cells, which can be reversed by phosphatase
treatment (Lin et al., 1992; Kramer et al., 1993; Qiu et al., 1993). Subsequently, the
phosphorylation of cPLA2 was shown to be mediated by p42/44
MAPK and to occur on Ser505
(Nemenoff, et al., 1993; Lin, et al., 1993) which is situated in the MAPK consensus site.
The importance of this phosphorylation site was demonstrated in Chinese hamster ovary
cells overexpressing mutant cPLA2, in which Ser
505 is substituted by Ala. This mutant could
not be phosphorylated and evoke agonist-induced arachidonic acid release (Lin, et al.,
14
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1993). However, cPLA2 phosphorylation induced by different stimuli in various cells
without a concomitant increase in intracellular calcium does not result in arachidonic acid
release, demonstrating that both calcium signalling and phosphorylation are necessary for a
full activation of cPLA2 (Murakami et al., 1997). Moreover, phosphorylation of cPLA2 has
to precede an increase in intracellular calcium to achieve maximal activity (Schalkwijk et
al., 1996) implying that cPLA2 may not be available for phosphorylation when it is first
translocated. In line with this is the hypothesis that phosphorylation of Ser505 might cause
conformational changes in cPLA2 since Ser
505 is situated between the CaLB and catalytic
domains of cPLA2 (Dessen, et al., 1999). It is now becoming clear that p42/44
MAPK is not
the only MAPK family member involved in cPLA2 phosphorylation and activation. For
example, in the human astrocytoma cell line 1321N1, stimulation with thrombin or TNF-α
resulted in a phosphorylation and concomitant activation of cPLA2 which is most likely
mediated by the c-Jun NH2-terminal kinase (JNK) (Hernández et al., 1997; Hernández et al.,
1999; van Putten et al., 2001). Likewise, cPLA2 activity was blocked in thrombin, collagen
or stress-activated platelets that had been treated with an inhibitor for p38MAPK (Waterman
et al., 1996; Kramer et al., 1996; Börsch-Haubold et al., 1997; Buschbeck et al., 1999). The
phosphorylation sites in agonist-stimulated platelets and HeLa cells were analysed and
phosphorylation was found to occur on both Ser505 and Ser727, although it was suggested
that Ser727 is not directly phosphorylated by p38MAPK (Börsch-Haubold et al., 1998).
Ser727 lies in the consensus motif for basotrophic kinases such as PKC. The
involvement of PKC in cPLA2 activation has been observed in a variety of cell types
including macrophages, mesangial cells and thyroid cells (Huwiler & Pfeilschifter, 1993;
Qiu & Leslie, 1994; Ekokoski et al., 2000). Furthermore, PKC was shown to phosphorylate
recombinant cPLA2 in vitro directly, although it activated cPLA2 only minimally (Lin, et al.,
1993; Nemenoff, et al., 1993). It is now known, however, that PKC can trigger MAPK
activation and thus activate cPLA2 indirectly (Ekokoski, et al., 2000). In contrast, okadaic
acid induces cPLA2 phosphorylation of Ser
727 and arachidonic acid release without elevated
calcium levels, and an inhibitor of p38MAPK resulted in a reduced Ser505 and Ser727
phosphorylation in thrombin-activated cells. The kinase responsible for Ser727
phosphorylation of cPLA2 is a downstream substrate of p38
MAPK and has recently been
identified as the MAP Kinase Interaction Protein Kinase 1 (Mnk1) (Hefner et al., 2000).
Regulation of cPLA2 via a cluster-monomer concept.
Arachidonic acid has been shown to be involved in various cellular responses, such
as proliferation (Piomelli, 1993), inflammation (Heller, et al., 1998) and cytotoxicity
(Cifone et al., 1993). Since arachidonic acid is preferentially released by cPLA2, its activity
has to be tightly controlled. In most inflammatory cells, a significant amount of cPLA2
translocates from the cytosol to the perinuclear region upon its activation (Peters-Golden &
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McNish, 1993; Glover, et al., 1995), whereupon arachidonic acid is released and converted
into eicosanoids. In other cells, not primarily involved in eicosanoid synthesis, cPLA2
appeared to be localised predominantly in clusters near organellar membranes. Upon
stimulation, these clusters did not massively translocate to a specific organel (Bunt et al.,
1997). We further investigated this phenomenon, using cPLA2 monomers obtained by gel
filtration chromatography as described previously (Spaargaren et al., 1992) and
homogenates of Her14 fibroblasts. A 200.000xg particulate fraction was subjected to
electron microscopical immunogold detection of cPLA2 complexed to its antibody which
revealed the presence of both cPLA2 clusters and monomers, however, only cPLA2
monomers could occasionally be detected at membranes. The calcium-dependent membrane
16
Chapter 1
0
1000
2000
3000
4000
5000
6000
7000
8000
Control Ca2+ EGTA
[1
4  C
]-
a
ra
ch
id
o
n
ic
 a
ci
d
 r
e
le
a
se
 (
d
p
m
)
A B
C
Figure 2. Ca2+-dependent membrane binding by cPLA2 monomers as observed with the electron
microsope is related with hydrolytic activity. cPLA2 monomers bind Ca
2+-dependently to SAPC
MLV's (A; 1 mM Ca2+, B; 1 mM EGTA) and exhibit Ca2+-dependent arachidonic acid release under
the same conditions (C).
binding of cPLA2 monomers as well as its activity measured in vitro, using the conditions
of the electron microscopical studies, was investigated towards multi lamellar vesicles
(MLVs) composed of 1-stearoyl-2-arachidonoyl phosphatidylcholine in the presence of
Ca2+ or EGTA. Figure 2 shows only binding of cPLA2 monomers to MLVs in the presence
of Ca2+ (fig. 2A) while no binding was observed in the presence of EGTA (fig. 2B). In
addition, arachidonic acid release was only detected in the presence of calcium (fig. 2C).
From these results we conclude that the clusters represent an inactive pool of cPLA2 from
which monomers can be recruited that are only active when bound to membranes.
Furthermore, Schalkwijk et al. (1996) demonstrated in Her14 fibroblasts that
phosphorylation of cPLA2 has to precede an increase in intracellular calcium levels for
maximal cPLA2 activation. Collectively, these data lead to the following hypothesis.
Phosphorylation of clustered cPLA2 leads to a local release of cPLA2 monomers that
subsequently can translocate to the nearby membranes by the increase of intracellular
calcium and then become fully active (Bunt et al., 2000). Thus cPLA2 activation by this
model does not lead to a massive translocation and activation of cPLA2 but is locally and
strictly regulated.
Signal transduction
The p42/44MAPK pathway.
Mammalian cells respond to many extracellular signals thereby activating protein
kinase cascades to amplify the signal. Thus allowing the cells to integrate these signals
resulting into a cellular response. Components of such a cascade are members of the
mitogen-activated protein kinase (MAPK) family, which are serine/threonine protein
kinases activated by various stimuli. The MAPK family can be divided into five families:
p42/44MAPK, p38MAPK, JNK, ERK3/4 and ERK5 (Widmann et al., 1999). The p42/44MAPK
play an important role in several cellular processes, including cell proliferation, cell cycle
regulation, cell survival and differentiation. Furthermore, p42/44MAPK can be activated by
various stimuli such as growth factors, cytokines and oxidative stress. The activation of
p42/44MAPK by these stimuli is either exerted through protein-tyrosine kinase receptors or
G-protein coupled receptors. 
Growth factors like EGF, platelet-derived growth factor (PDGF) and fibroblast
growth factor (FGF) bind to the receptors, whereupon the receptors dimerise, resulting in
autophosphorylation of tyrosine residues in the intracellular domains of the receptors
(Schlessinger & Ullrich, 1992; Fantl et al., 1993). These phosphorylated tyrosine residues
may act as high-affinity docking sites for substrates such as pp60c-Src, phosphoinositide-
specific phospholipase Cγ (PLCγ), Shc, growth factor receptor-bound protein 2 (Grb2) and
17
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phosphatidylinositol-3-kinase (PI3K) (Anderson et al., 1990; Lowenstein et al., 1992; Hu et
al., 1992; Wolf et al., 1995) either to transduce the signal directly further or by recruiting
other proteins to the receptor (fig. 3). In case of PLCγ, plasma membrane
phosphatidiylinositol-4,5-bisphosphate (PIP2) becomes hydrolysed into inositol-1,4,5-
trisphosphate (IP3) and diacylglycerol (DAG). IP3 releases calcium from internal stores,
which together with DAG can activate certain protein kinase C (PKC) isoforms. PKCs have
been implicated in many biological processes including cell morphology, proliferation and
differentiation (Hug & Sarre, 1993; Nishizuka, 1995; Jaken, 1996; Livneh & Fishman, 1997).
Grb2 recruits the guanine-nucleotide exchange factor sos to the plasma membrane
to bring sos in close proximity with ras (Egan et al., 1993), a small GTP-binding protein
located at the cytoplasmic surface of the plasma membrane (Margolis & Skolnik, 1994).
18
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Figure 3. Growth factor-induced signal transduction pathways leading to ERK1/2 activation.
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Sos, subsequently, promotes the release of GDP from the inactive ras-GDP complex,
allowing GTP to bind which renders ras active (Bonfini et al., 1992). However, Shc is also
able to bind both the receptor and Grb2 serving as another mechanism to recruit sos to the
plasma membrane, resulting in ras activation (van der Geer & Pawson, 1995). Once ras is
activated it binds to the serine/threonine kinase Raf-1, translocating Raf-1 to the plasma
membrane, whereafter it can be tyrosine phosphorylated by membrane-bound tyrosine
kinases including c-Src (Marais et al., 1995; Marais & Marshall, 1996). In addition to
tyrosine phosphorylation, Raf is phosphorylated on serine residues and on a threonine
residue (Marais & Marshall, 1996). There is evidence showing that Raf-1, in cells activated
by various growth factors, can be phosphorylated by several different PKC isoforms (Kolch
et al., 1993; Morrison et al., 1993; van Dijk et al., 1997; Hausser et al., 2001). Mutation of
specific serine phosphorylation sites on Raf does not prevent phorbol ester activation in
transfected cells, however (Schönwasser et al., 1998; Whitehurst et al., 1995). When
activated, Raf activates MAPK kinase 1 (MEK1) and 2 (MEK 2) by serine phosphorylation
(Alessi et al., 1994; Zheng & Guan, 1994), who in turn phosphorylate and thereby activate
p42MAPK (or ERK2) and p44MAPK (or ERK1) on threonine and tyrosine residues (Payne et
al., 1991; Seger et al., 1992; Wu et al., 1993). Recently, it was demonstrated that both
MEK1/2 and ERK1/2 activation was mediated by PKC in growth factor-stimulated cells
(Grammer & Blenis, 1997; Adomeit et al., 1999; Hausser, et al., 2001). However, a direct
activation or p42/44MAPK is unlikely since PKC is only able to phosphorylate serine and
threonine residues and both threonine and tyrosine residues have to be phosphorylated for
full activity of p42/44MAPK (Seger & Krebs, 1995). Furthermore, PI3K was found to be
involved in both MEK1/2 and ERK1/2 activation (Grammer & Blenis, 1997; Conway et al.,
1999). 
Cell cycle regulation.
The cell cycle is the set of events responsible for the duplication of the cell and
consists of four phases. The S phase, in which the DNA is duplicated; the M phase, in which
the duplicated DNA is segregated between the two daughter cells; and two gap phases, G1
before S phase and G2 before M phase. Progression through these phases is regulated by
cyclin-dependent kinases (Cdks) and binding with their regulatory subunits, designated
cyclins, by multiple phosphorylation and dephosphorylation events (Nigg, 1995; Dirks &
Rutka, 1997; Reed, 1997). These cyclin/Cdk complexes regulate passage from one phase to
another, for the cell to proliferate, but are also involved in the processes of cell
differentiation, senescence and quiescence. Signal transduction pathways activated by
signals from the extracellular environment determines the process to be activated.
Progression through the cell cycle is dependent both on the presence of growth factors and
on cell attachment. For instance, adherent cells in the presence of growth factors continue
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to proliferate. However, if cells are deprived of serum, they will stop progressing through
the cell cycle, whereupon exit into the quiescent (G0) state occurs (Pardee, 1974). Normal
growing cells, or quiescent cells re-entering the G1 phase of the cell cycle, require growth
factors until the restriction point (R), to complete the cell cycle (Pardee, 1974). 
Mammalian cells contain at least nine Cdks which are required to regulate the cell
cycle (fig. 4) (Nigg, 1995; Bagella et al., 1998). The first cyclin/Cdk complex is activated
by growth factors in G1 and consists of a D-type cyclin (cyclin D1, D2 or D3) and Cdk4 or
6 (Sherr, 1995). Activation of the cyclin D/Cdk complex, as well as a c-myc-mediated
pathway (Bartek & Lukas, 2001), results in the expression of cyclin E and association with
Cdk2 to mediate retinoblastoma (Rb) hyperphosphorylation. Cyclin E/Cdk2 expression and
activation is both rate-limiting and essential for S phase entry (Bartek et al., 1996; Sherr &
Roberts, 1999). Retinoblastoma phosphorylation results in the release of the transcription
factor E2F and the subsequent induction of genes that mediate progression through S phase,
like cyclin A and thymidylate synthase (DeGregori et al., 1995). In addition, activation of
these complexes is also regulated by a group of proteins called Cdk inhibitors (CKIs) which
consists of two families. Members of the INK4 family (inhibitors of Cdk4; comprising of
p15, p16, p18 and p19) bind to Cdk4, whereas members of the CIP/KIP family (comprising
of p21, p27 and p57) bind to Cdk2, 4 and 6 (reviewed in Arellano & Moreno, 1997;
Hulleman & Boonstra, 2001). Cyclin E/Cdk2 complexes are degraded in early S phase,
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Figure 4. Schematic representation of the regulatory events for cell cycle progression of
mammalian cells.
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whereafter Cdk2 associates with cyclin A. The activity of cyclin A/Cdk2 is necessary for
progression through S and is possibly involved in phosphorylation of transcription factors
and proteins required for DNA duplication (Cardoso et al., 1993; Fotedar & Fotedar, 1995).
Later on, complexes are formed of Cdk1 or Cdc2, with cyclin A, that is required for mitosis
until mid prophase (Furuno et al., 1999). Cyclin B/Cdk1 complexes until the G2/M
transition are held inactive by phosphorylation of Cdk1 (Mueller et al., 1995), which then
is dephosphorylated by cdc25C resulting in Cdk1 activation and progression into mitosis
(Kumagai & Dunphy, 1991). Cyclin B degradation is necessary for the cells to exit from
mitosis.
The activation of the Cdk by cyclin D depends on cyclin D expression that is
synthesised as long as growth factors are present (Sherr, 1994). Furthermore, activated
p42/44MAPK was shown to induce the expression of cyclin D and down-regulation of p27KIP
to exit from G0, and enter the G1 phase (Ladha et al., 1998). Also other components of the
ras-MAPK pathway have been shown to be involved in the regulation of cyclin D and
p27KIP (Aktas et al., 1997; Peeper et al., 1997; Cheng et al., 1998). The activation of
p42/44MAPK occurs through both growth factor- and extracellular matrix-induced signal
transduction pathways (Schwartz et al., 1995; Roovers et al., 1999; Hulleman & Boonstra,
2001), probably to obtain the sustained p42/44MAPK activation that is required to pass the
restriction point. Similarly, inhibition of the p42/44MAPK pathway by either antisense
constructs, overexpression of kinase-inactive mutants or inhibiting nuclear translocation of
p42/44MAPK by inhibitors, blocks DNA synthesis and proliferation (Pagès et al., 1993;
Brondello et al., 1995;(Hulleman et al., 1999). On the other hand, activation of this same
pathway may also lead to cell cycle arrest, depending on the level of the activated Raf-
MAPK pathway (Woods et al., 1997; Sewing et al., 1997; Pumiglia & Decker, 1997).
Moreover, overexpression of p42/44MAPK has been found in human breast cancer
(Sivaraman et al., 1997), and also Cdc25A, cyclin D and E, myc and Rb are upregulated in
several cancers (Gasparotto et al., 1997; Kornmann et al., 1998; Spruck et al., 1999;
Hanahan & Weinberg, 2000). 
Physiology of the arachidonic acid cascade 
Arachidonic acid is the main polyunsaturated fatty acid in the production of
eicosanoids, which are oxygenated C18, C20 and C22 carbon fatty acids. The pathways
leading to these eicosanoids is collectively known as the arachidonic acid cascade and
consists of three major pathways including cyclooxygenase, lipoxygenase and epoxygenase
pathways, named after the first enzymatic step involved. The conversion of arachidonic acid
by one of these pathways depends on the cell type (Shimizu & Wolfe, 1990). Eicosanoids
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are not stored but synthesised on demand in which the release of arachidonic acid by PLA2
is the rate-limiting step.
Physiological roles of cPLA2 using gene knock-outs.
To gain more insight in the physiological roles of cPLA2, a homozygous null mouse
(cPLA2
-/-) was created (Bonventre et al., 1997; Uozumi et al., 1997). The cPLA2
-/- mice
appeared to be normal, indicating that cPLA2 is not necessary for normal embryonic
development. However, there could be other compensatory influences that maintain a
normal development in the absence of cPLA2, although later on it was found that the cPLA2
-/-
females were unable to reproduce. Likewise, the COX-deficient mice also showed
reproductive abnormalities and mice lacking the PGF2α receptor did not come into labour
(Sugimoto et al., 1997). Furthermore, cPLA2
-/- mice had a reduced brain infarct volume and
fewer functional neurogenic deficits after induction of cerebral ischemia and reperfusion.
Also the cPLA2
-/- mice were more resistant to MPTP-induced neurotoxicity, that produces a
Parkinsonian syndrome in human and non-human primates (Bloem et al., 1990). These
results suggest a role for selective cPLA2 inhibitors for the treatment of stroke and
Parkinsons disease. cPLA2
-/- mice recover faster from allergen-induced
bronchoconstriction and show no airway hyperresponsiveness. Moreover, the eicosanoid
generation from peritoneal macrophages and both the immediate and delayed phases of bone
marrow-derived mast cells are impaired (Uozumi, et al., 1997; Bonventre, et al., 1997;
Fujishima et al., 1999).
Cyclooxygenase pathway.
Arachidonic acid can be converted into prostaglandin H2 (PGH2) by the action of
cyclooxygenase-1 (COX-1 or prostaglandin H synthase-1 (PGHS-1)) or cyclooxygenase-2
(COX-2 or PGHS-2) that can be further transformed into prostaglandins (PG) or
thromboxanes (TX) (fig. 5) (Smith, 1989). Although many different prostanoids exist, their
synthesis is cell type specific (Smith et al., 1991). For example thromboxane A2 (TXA2) is
mainly formed in platelets, while prostacyclin (PGI2) is the major prostanoid in endothelial
cells and prostaglandin E2 (PGE2) is mainly present in renal collecting tubule cells. COX-1
is found to be constitutively expressed in most cells and tissues and is involved in cellular
housekeeping processes and thrombosis (Patrignani et al., 1994). By contrast, COX-2 is
mainly inducibly expressed in activated cells and is amongst others, involved in
inflammation, pain and fever (Riendeau et al., 1997; Zhang et al., 1997), various cancers
(Kargman et al., 1995; Levy, 1997) and Alzheimers disease (McGeer & McGeer, 1999).
Both enzymes have a similar structure, convert arachidonic acid into PGH2 with almost
identical kinetics and exist often in the same cells and tissues. The reason for the presence
of two COX enzymes is now becoming clear from studies of knock-out mice for COX-1 and
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Figure 5. Eicosanoids generated by enzymes of the arachidonic acid cascade.
COX-2 (Langenbach et al., 1999) as well as from studies with isozyme selective inhibitors
(DeWitt, 1999). The current idea is that prostanoids formed via COX-2 can signal uniquely
through G-protein-coupled receptors and through a nuclear pathway, while products derived
via COX-1 most likely only signal through other cell surface receptors. In stimulated cells
a biphasic generation of prostanoids occurs in which the initial phase is COX-1 dependent
and the delayed phase of slow prostanoid production depends on COX-2 induction (Reddy
& Herschman, 1997; Kuwata et al., 1998). Thus, the function of the enzymes is more or less
related with the regulation of their expression.
Since COX-1 had been considered a housekeeping cyclooxygenase it was
surprising that the knock-out mice were generally healthy. However, these mice showed, for
instance, a decreased platelet aggregation in response to arachidonic acid because
thromboxanes could not be formed. Also prostaglandins in placenta and/or fetal tissue were
found to be critical for parturition (Langenbach et al., 1995).
The COX-2 knock-out (COX-/-) mice develop severe nephropathology within the
first 6 weeks of life (Morham et al., 1995) which fortunately becomes less severe in later
generations (Lim et al., 1999), possibly due to adaptation processes. In contrast to COX-1
knock-out mice, the COX-2-/- mice display abnormalities in every phase of the reproductive
process (Lim et al., 1997). Furthermore, from patient studies a relation between the intake
of non-steroidal anti-inflammatory drugs (NSAIDs) and the development of colorectal
cancer was found. Indeed, in colorectal cancers the expression of COX-2 but not COX-1
was elevated (Williams et al., 1999). Also breast and lung cancer cells have been found to
synthesise large amounts of prostaglandins of which PGE2 is the major prostaglandin
produced by tumour cells (Ara & Teicher, 1996). In animal model studies, cyclooxygenase
inhibitors exhibited chemopreventive effects as the number and size of the tumours per
animal decreased. Also prostaglandins itself can have anti-tumour activity. For example, a
10 day infusion of PGE1 in Lewis lung carcinoma mice resulted in a significant reduction in
tumour volume, weight, the number of metastasis and the doubling time of the tumour (Ellis
et al., 1990).
Lipoxygenase pathway.
Lipoxygenases catalyse the insertion of oxygens in various eicosaenoic acids and
in the case of arachidonic acid, this will lead to hydroperoxy-eicosatetraenoic acids
(HpETEs). In mammalian cells three major lipoxygenases have been identified according to
the oxygenation sites in arachidonic acid, i.e.; 5-lipoxygenase (5-LO), 12-lipoxygenase (12-
LO) and 15-lipoxygenase (15-LO) resulting in 5(S)-, 12(S)-, and 15(S)-HpETE (fig. 5).
These HpETEs can subsequently undergo several different enzymatic transformations
resulting in the production of dihydroxy-eicosatetraenoic acids (DiHETEs), epoxy fatty
acids (leukotrienes) and trihydroxy-eicosatetraenoic acids (lipoxins) (Smith et al., 1991). 
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5-LO is present in a variety of inflammatory cells, among them are leukocytes,
neutrophils, basophils and monocytes (Chen et al., 1995; Brock et al., 1995; Pouliot et al.,
1996), but is also found in human placenta (Matsumoto et al., 1988). In line with the
presence of 5-LO in these cells is that 5-LO has been shown to be involved in inflammation
and asthma by the production of the biologically potent leukotrienes (LT) (Ford-Hutchinson,
1990; Lewis et al., 1990). To investigate the function of 5-LO in more detail, knock-out
mice were developed. However, the 5-LO deficient mice grew normally, were fertile and no
obvious alteration in the phenotype was observed compared to control mice (Chen et al.,
1994). Later on it was found that in these mice 5-LO products are required for the
development of airway hyperresponsiveness and are partially involved in antigen
challenged eosinophil recruitment (Corry et al., 1996; Drazen et al., 1996; Foster et al.,
1996). Furthermore, these studies in 5-LO-/- mice revealed the involvement of 5-LO in host
defense (Goldhill et al., 1997) and in acute inflammation, although the nature of the stimuli
and the location were found to be important.
The functions of the 12- and 15-LO are not well understood since the action of each
enzyme can result in the same two products although they have been implicated in
intracellular organel degradation, erythrocyte maturation and atherosclerosis (Kühn &
Brash, 1990).
Three classes of 12-LOs have been identified which are the platelet type (P12-LO),
leukocyte type (L12-LO) and epidermal type (E12-LO). 12-LOs have been found in a
variety of tissues including platelets, keratinocytes, leukocytes, A431 epidermal carcinoma
cells and other tumour cells (Yoshimoto & Yamamoto, 1995; Funk, 1996). Also the L12-LO-/-
mice grew normally and were fertile, indicating that 12-LO is not essential for fetal
development. In addition, hardly any 12-HETE and 15-HETE products were detected in 12-
LO-/- macrophages but a 5-HETE product instead (Sun & Funk, 1996), indicating that
disturbing one pathway can lead to enhancement of another one. 12-HETE modulates
neurotransmission (Piomelli et al., 1987) and cell adhesion (Tang et al., 1995) which are fast
events, but is also involved in long term events such as platelet aggregation, cell
differentiation or survival (Yu et al., 1995; Tang et al., 1996).
The 15-LO exist in reticulocytes, airway epithelium (Funk, 1996) and is
upregulated in a number of tumour cells (Kamitani et al., 1998; Shappell, et al., 2001) . 15-
LO is not only thought to be involved in inflammation (Samuelsson et al., 1987;
Vanderhoek, 1988), but also in reticulocyte differentiation (Schewe & Kühn, 1991; Nadel et
al., 1991) and atheroma formation (Feinmark & Cornicelli, 1997). Furthermore, 15-LO can
peroxidise membrane lipids thereby changing the structure and function of lipid-protein
complexes as is the case in reticulocyte maturation and in the formation of atherosclerotic
plaques (Schewe and Kühn, 1991; Nagy et al., 1998).
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Epoxygenase pathway.
The epoxygenase pathway is initiated by transforming arachidonic acid via
cytochrome p450 mixed-function oxidases finally resulting in cis-epoxy-eicosatrienoic
acids (EpEtrEs or EETs), hydroxy-eicosatetraenoic acids (HETEs) and hydroxy-
eicosatetraenoic acids (OH-AA) (Capdevila et al., 1992) (fig. 5). As opposed to the
cyclooxygenase and lipoxygenase enzymes, the biological and molecular characterisations
of the cytochrome p450 preceded the functional studies which have only recently started to
be investigated. In animal functions and organs the cytochrome p450 metabolites have been
implicated to mediate the release of peptide hormones, to be mediators of salt and water
regulation by the kidney and to be involved in vascular tone, although these results are
conflicting (Capdevila, et al., 2000). On the cellular level, cytochrome p450 metabolites
have been found to be involved in ion channels and transporters and to act as mitogens
(Capdevila, et al., 2000). Furthermore, a role for cytochrome p450 has been proposed in
hypertension (Rahman et al., 1997).
Eicosanoids can contribute to normal physiologic processes such as inflammation,
development and immune function but also to non-physiological processes as in diseases
and carcinogenesis. Future experiments are needed to elucidate the specific roles and
mechanisms by which these eicosanoids act. However, the biosynthesis of these eicosanoids
depends on the availability of free arachidonic acid of which the release is controlled by the
action of PLA2s and especially cPLA2. Thus, it appears that the function of cPLA2 in these
processes plays an even more important role.
Scope of this thesis
Arachidonic acid is involved in numerous physiological and pathophysiological
processes and is preferentially released by cPLA2, implicating that cPLA2 activity has to be
tightly regulated. The aim of this study was to gain more insight in the regulation of cPLA2
in mitogen- and oxidative stress-induced cells, as well as in continuously cycling cells.
Furthermore, the possible role of cPLA2 and the downstream arachidonic acid metabolising
enzymes, cyclooxygenases and lipoxygenases, in cell cycle progression was investigated. 
Chapter 2 deals with the regulation of cPLA2 in serum- and EGF-activated cells as well as
in quiescent and proliferating cells. cPLA2 in both serum- and EGF-stimulated cells is
activated by p42/44MAPK, that in turn is activated differentially involving the Raf-MEK
pathway and PKC, but not PI3K. In contrast, p42/44MAPK phosphorylation in quiescent and
proliferating cells is solely achieved via the Raf-MEK pathway, but only leads to cPLA2
activation in quiescent cells. These data suggest the activation of different populations of
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p42/44MAPK and cPLA2. The results in chapter 3 show that cPLA2 is activated by different
kinds of oxidative stress. H2O2-induced cPLA2 activation is partly mediated by
phosphorylation through the Raf-MEK-p42/44MAPK pathway and partially by a
phosphorylation-independent mechanism, likely involving lipid peroxidation. In chapter 4
the activation of cPLA2 during the ongoing cell cycle was investigated. cPLA2 activity was
high in mitosis, decreasing rapidly in early G1. A small increase was observed in mid/late
G1, followed by a strong increase at the G1/S transition. The changes in cPLA2 activity were
not due to a difference in cPLA2 expression, but due to phosphorylation of cPLA2 by
p42/44MAPK. The possible role of cPLA2 activity in cell cycle progression was studied in
chapter 5. Inhibiting cPLA2 activity in early G1 using ATK, an inhibitor for cPLA2, resulted
in a marked reduction in DNA synthesis. However, no significant difference in total cell
number was counted in ATK treated cells for 24h compared to control cells. Furthermore,
inhibition of cyclooxygenases at different time points after mitosis did not have any effect
on cell cycle progression, whereas inhibition of lipoxygenases result in cell cycle arrest.
Moreover, lipoxygenases are required for S phase progression, since no DNA synthesis
occurred when lipoxygenase was inhibited. Finally, in chapter 6 the purpose of different
signal transduction pathways regulating cPLA2 activity and the possible functions of cPLA2
and lipoxygenase actions for cell cycle progression will be discussed.
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Abstract 
Arachidonic acid has been implicated to play a role in physiological and
pathophysiological processes and is selectively released by the 85 kDa cytosolic
phospholipase A2 (cPLA2). The activity of cPLA2 is regulated by calcium, translocating
the enzyme to its substrate, and by phosphorylation by a mitogen-activated protein
kinase (MAPK) family member and a MAP kinase-activated protein kinase. In this
study, the signal transduction pathways in growth factor-induced phosphorylation of
p42/44MAPK and cPLA2 activation was investigated in Her14 fibroblasts. p42/44
MAPK in
response to epidermal growth factor was not only phosphorylated via the Raf-MEK
pathway but mainly through protein kinase C (PKC), or a (un)related kinase, in which
the phosphorylated p42/44MAPK corresponded with cPLA2 activity. Serum-induced
phosphorylation of p42/44MAPK also corresponded with cPLA2 activity but is
predominantly mediated via Raf-MEK and partly through PKC, or a (un)related
kinase. In contrast, activation of PKC by phorbol ester did not result in increased
cPLA2 activity while p42/44
MAPK is phosphorylated, mainly via Raf-MEK and through
MEK. Moreover, p42/44MAPK phosphorylation is present in quiescent and proliferating
cells that is entirely phosphorylated via Raf-MEK but only corresponds to cPLA2
activity in the former cells. Collectively, these data show that p42/44MAPK in
proliferating, quiescent and stimulated cells is phosphorylated by various signal
transduction pathways suggesting the activation of different populations of
p42/44MAPK and cPLA2.
Introduction
Phospholipases A2 (PLA2) release fatty acids from the sn-2 position of
phospholipids. This is of particular interest when arachidonic acid is released since it plays
a central role in various cellular processes such as cell migration, mitogenic signalling
(Piomelli, 1993; Korystov Yu et al., 1998), inflammation (Heller et al., 1998) and
cytotoxicity (Wissing et al., 1997; Grazia Cifone et al., 1997). This arachidonic acid is
preferentially released by the 85 kDa cytosolic phospholipase A2 (cPLA2) (Clark et al.,
1995; Sharp et al., 1991) and therefore cPLA2 activity has to be tightly controlled. 
cPLA2 activity is regulated by both calcium and phosphorylation. Submicromolar
concentrations of calcium are required for cPLA2 to translocate from the cytosol towards
phospholipid membranes that is mediated by its calcium-dependent phospholipid binding
domain (Nalefski et al., 1994). cPLA2 phosphorylation was found to occur on Ser-505
through a mitogen-activated protein kinase (MAPK) (Clark, et al., 1995 and references
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therein) and the importance of cPLA2 phosphorylation was shown in several other studies
using a cPLA2 gel shift (Qiu & Leslie, 1994; Sa et al., 1995; Clark, et al., 1995 and
references therein). The phosphorylation causes an increase in the intrinsic activity (Kramer
et al., 1993; Schalkwijk et al., 1995) and can be reversed by phosphatase treatment
(Schalkwijk, et al., 1995; Wijkander & Sundler, 1992). In platelets, p38MAPK has been
shown to phosphorylate cPLA2 (Kramer et al., 1996) on Ser-505 (Börsch-Haubold et al.,
1998) and for a full activation cPLA2 must also be phosphorylated on Ser-727 by a Mnk1-
related protein kinase (Hefner et al., 2000). p42/44MAPK was the first MAPK family member
shown to phosphorylate cPLA2 on Ser-505 (Lin et al., 1993) and phosphorylation of cPLA2
has been correlated with p42/44MAPK phosphorylation in many cell models (Clark, et al.,
1995; Hirabayashi & Shimizu, 2000).
Stimulation of cells by epidermal growth factor (EGF) results in the activation of
cPLA2 (Spaargaren et al., 1992; Bonventre et al., 1990). Subsequently, it was reported that
in EGF-activated Herc13 and Her14 fibroblasts cPLA2 was phosphorylated and this
phosphorylation had to precede a rise in the intracellular calcium concentration for the
enzyme to become maximal active (Schalkwijk, et al., 1995; Schalkwijk et al., 1996).
Moreover p42/44MAPK in these cells was also phosphorylated after EGF stimulation in a
similar time course. Therefore, we investigated whether EGF-induced p42/44MAPK
phosphorylation in Her14 cells results in cPLA2 activation. p42/44
MAPK, upon growth factor
stimulation of cells is generally thought to become activated through p21ras, following the
sequential activation of Raf-1 and MAPK kinase (MEK) (Bokemeyer et al., 1996; Haystead
et al., 1992; Marshall, 1995). However, it has recently been demonstrated that p42/44MAPK
cannot only be phosphorylated through Raf-MEK but also by phosphatidylinositol-3-kinase
in platelet-derived growth factor (PDGF)-stimulated airway smooth muscle cells or Swiss
3T3 fibroblasts (Grammer & Blenis, 1997; Conway et al., 1999). Moreover, activation of
p42/44MAPK by protein kinase C has also been reported (Hirabayashi & Shimizu, 2000).
Hence, we have established the signal transduction pathways involved in the
phosphorylation of p42/44MAPK in EGF-stimulated Her14 fibroblasts. 
We observed that the measured activity of cPLA2 in quiescent cells varied between
several experiments which may also explain the difference in stimulation of cPLA2 activity
in cells upon EGF treatment, as has been reported previously (Kramer, et al., 1993; Lin et
al., 1992). In addition, the level of phosphorylated p42/44MAPK in quiescent cells was
variable between different experiments and corresponded with cPLA2 activity. This
remaining phosphorylation of p42/44MAPK was not due to non-quiescent cells, because, the
p42/44MAPK, that was activated via the Raf-MEK pathway in proliferating cells did not
result in cPLA2 activation. Furthermore, stimulation of quiescent cells with serum resulted
in p42/44MAPK phosphorylation and subsequent cPLA2 activation, as was the case in EGF-
but not in phorbol ester-activated Her14 fibroblasts. The signal transduction pathways
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leading to p42/44MAPK phosphorylation involve to variable degrees Raf-MEK and protein
kinase C (PKC) but not phosphatidylinositol-3-kinase.
Materials and Methods
Materials.
Tissue culture nutrients, Dulbeccos modified Eagles medium (DMEM) and foetal
bovine serum (FBS) were purchased from Gibco BRL (Scotland). Ro31-8220, phorbol-12,
13-dibutyrate (PdBu), Gö6983 and Gö6976 were from Calbiochem (La Jolla, USA).
PD098059 and U0126 were obtained from Biomol (Playmouth meeting, USA) and Promega
(Madison, USA), respectively. LY294002 was from Alexis (Läufelfingen, Switzerland) and
Protifar was from Nutricia (Zoetermeer, The Netherlands). Staurosporine, wortmannin and
dipalmitoylglycerol were purchased from Sigma (Steinheim, Germany). 1-Stearoyl-2-[1-
14C]arachidonoyl-glycero-3-phosphocholine was obtained from Amersham
(Buckinghamshire, England) and epidermal growth factor (EGF) was from Harlan
Bioproducts (Madison, USA). All other chemicals were either from Sigma or Merck
(Darmstadt, Germany).
Cell culture.
Her14 cells, which are mouse NIH3T3(0) fibroblasts transfected with the human
EGF-receptor cDNA, were grown in DMEM supplemented with 7.5% FBS. Cells were
maintained at 37°C in a humidified atmosphere. Cells were grown to a confluency of 30,000
cells/cm2, whereafter they were serum-starved overnight. Next, the cells were stimulated
with FBS (5%), EGF (50 ng/ml) or PdBu (200 nM) for 15 min or for the indicated times.
Treating the cells with PD098059 (50 µM) or U0126 (50 µM) 1 h prior to stimulation
inhibited MEK activity. Phosphatidylinositol-3-kinase (PI3K) inhibition was performed by
treating the cells with wortmannin (10 nM) or LY294002 (10 µM) 30 min prior to
stimulation. Protein kinase C (PKC) was inhibited with either Ro31-8220 (10 µM),
staurosporine (1 µM), Gö6983 (10 µM) or Gö6976 (10 µM) for a 30 min pre-treatment.
Alternatively, it was down-regulated by prolonged treatment with PdBu (200 nM) for 24 h
prior to stimulation. After stimulation the cells were washed twice with ice-cold phosphate
buffered saline (PBS) whereafter the cells were scraped in homogenisation buffer (50 mM
Hepes/NaOH pH 7.4, 0.25 M sucrose, 50 mM NaF, 250 µM Na3VO4, 1 mM EGTA, 10 µM
leupeptin, 1 µM pepstatin and 1 mM PMSF). The cell lysate was homogenised by 15 strokes
through a 26G-needle and sonicated for 3 times 10 seconds. The amount of protein was
measured according to Bradford (1976) using a Bio Rad novapathTM microplate reader.
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Western blot analysis.
Cell homogenates (10 µg protein) were separated on 10% SDS-PAGE and
transferred to polyvinylidene difluoride membrane by semi-dry blotting using a BioRad
trans-blot SD. The membrane was blocked for 1h at RT with 2% milkpowder in PBST (PBS
containing 0.1% (v/v) Tween-20), followed by primary antibody incubations for 1h at RT in
0.2% milkpowder in PBST. Phosphorylated p42/44MAPK or phosphorylated MEK1/2 were
detected respectively with a phospho-p42/44 MAPK or a phospho-MEK1/2 rabbit
polyclonal antibody at a dilution of 1:1000 (New England Biolabs Incorporated, Beverly,
MA). MEK1 (0.25 µg/ml) or ERK2 (0.5 µg/ml) were detected with a monoclonal antibody
from Upstate Biotechnology (Lake Placid, NY) or from Transduction Laboratories
(Lexington, KY), respectively. Then, the membrane was washed and primary antibodies
were detected with goat anti-rabbit and rabbit anti-mouse IgG conjugated to horseradish
peroxidase and the bands were visualised with enhanced chemiluminescence (NENTM, Life
science products, Boston).
cPLA2 activity assay.
cPLA2 activity was measured by the release of radiolabeled arachidonic acid from
the sn-2 position of 1-stearoyl-2-[1-14C]arachidonoyl-glycero-3-phosphocholine as
described previously (Schalkwijk, et al., 1996). The radiolabeled phosphatidylcholine was
dried under N2 together with dipalmitoylglycerol and then dispersed in water by sonification
for 4 times 15 s under nitrogen to give final concentrations of 4 and 2 µM, respectively. The
assay incubation mixture contained 0.2 M Tris pH 8.5, 1 mM CaCl2, 5 mM DTT and 10 µg
cell homogenate in a total volume of 200 µl. After incubation for 7-10 min at 37°C the
released radiolabeled arachidonic acid was extracted by a modified Dole extraction
procedure (van den Bosch et al., 1974) and the radioactivity was determined in a
scintillation counter (Tri-Carb 15000, Packard, Meriden, USA). In this way only the activity
of cPLA2 was measured (Spaargaren, et al., 1992; Atsumi et al., 1998).
Results
Endogenous cPLA2 activity corresponds with p42/44
MAPK phosphorylation in quiescent
but not in proliferating cells.
We observed that the cPLA2 activity measured in quiescent cells varied between
several experiments that might result in a difference in cPLA2 stimulation (Qiu et al., 1993).
In addition, the level of phosphorylated p42/44MAPK in quiescent cells was also subject to
alterations. Since it has been previously reported that cPLA2 can be phosphorylated and
thereby activated by MAP kinase (MAPK) in a variety of cell models (Lin, et al., 1993;
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Nemenoff et al., 1993), the relation between p42/44MAPK phosphorylation and cPLA2
activity in quiescent cells was investigated. To ensure that the activation range of cPLA2 and
p42/44MAPK were identical between each condition within the experiment, the same batch of
cells was used for every experiment performed. A low phosphorylation of p42/44MAPK was
detected on western blot in quiescent cells (fig. 1A, lane 1), which was almost completely
vanished in quiescent cells that were treated for 1h with the MAPK kinase (MEK) inhibitor
PD098059 (fig. 1A, lane 2). PD098059 binds directly to the non-phosphorylated isoforms
of MEK (MEK-1 and 2), thereby preventing their Raf-mediated activation (Dudley et al.,
1995; Favata et al., 1998). Next, another MEK inhibitor, U0126 was used. U0126 inhibits
the catalytic activity of MEK (Favata, et al., 1998), although it can still be phosphorylated.
Treating quiescent cells for 1h with U0126 resulted in a complete loss of p42/44MAPK
phosphorylation (fig. 1A, lane 3). Subsequently, the activity of cPLA2 in these samples was
measured as described in Materials and Methods. Figure 1B shows that in quiescent cells
cPLA2 activity is present (-s) which gradually decreases upon treatment of these quiescent
50
Chapter 2
1 2 3 1 2 3A
B
pp42MAPK
pp44MAPK
0
250
500
750
1000
1250
-s -s pd -s u
treatment
c
P
L
A
2
 a
c
ti
v
it
y
 (
d
p
m
)
0
250
500
750
1000
1250
+s +s pd +s u
c
P
L
A
2
 a
c
ti
v
it
y
 (
d
p
m
)
C
D
treatment
pp42MAPK
pp44MAPK
Figure 1. Effect of the MEK inhibitors, PD098059 and U0126, on phosphorylated p42/44MAPK
and cPLA2 activity in quiescent and proliferating Her14 cells. Her14 cells were serum-starved
overnight (-s) or were continuously grown in medium containing serum (+s). Then these cells were
incubated for 1h with 50 µM PD098059 (pd) or U0126 (u), or were left untreated. p42/44MAPK
phosphorylation was detected on western blot, using an antibody against phosphorylated p42/44MAPK
(A, C) and cPLA2 activity was measured by an in vitro assay as described in Materials and Methods
of quiescent (B) and proliferating cells (D). Results shown are representative of three independent
experiments and S. D. are shown for cPLA2 activity.
cells with PD098059 (-s pd) and U0126 (-s u), respectively. These results show that
p42/44MAPK is still phosphorylated in quiescent cells, which was activated via the Raf-MEK
pathway and this phosphorylation appears to relate with cPLA2 activation. It might well be
that the phosphorylation of p42/44MAPK and the presence of cPLA2 activity in quiescent
cells is due to the fact that not all cells have reached the quiescent state. This suggests that
the level of phosphorylated p42/44MAPK in proliferating cells (cells that are continuously
grown in medium containing serum) would be higher. Indeed, p42/44MAPK phosphorylation
was significantly higher in proliferating cells (fig. 1C, lane 1) compared to quiescent cells
(fig. 1A, lane 1). Incubating proliferating cells with PD098059 almost completely inhibited
the phosphorylation of p42/44MAPK (fig. 1C, lane 2) while it was completely vanished in
U0126 treated cells (lane 3). Thus, p42/44MAPK in proliferating cells is predominantly
activated via the Raf-MEK pathway as was also observed in quiescent cells. However,
cPLA2 activity in proliferating cells (fig. 1D, +s) is not related with p42/44
MAPK
phosphorylation as the activity in proliferating cells did not decrease in cells treated with
PD098059 (+s pd) or U0126 (+s u). 
These results show the activation of p42/44MAPK via the Raf-MEK pathway in both
quiescent and proliferating cells. However, cPLA2 activity is only related with p42/44
MAPK
phosphorylation in quiescent cells suggesting that cPLA2 in proliferating cells is activated
through other pathways. Therefore, we have studied the signal transduction pathways
leading to p42/44MAPK phosphorylation and subsequent cPLA2 activation in EGF- and
serum-stimulated cells.
Time-dependent activation of p42/44MAPK and cPLA2 in serum-stimulated cells.
In order to establish whether p42/44MAPK and cPLA2 are activated by serum,
quiescent Her14 cells were incubated in the presence of serum for different periods of time.
Addition of serum (5%) to the cells resulted in a rapid phosphorylation of p42/44MAPK
within 5 min that decreased slowly afterwards (fig. 2A). The activity of cPLA2 in these cells,
measured as described in Materials and Methods, demonstrated a transient activation that
was already maximal at 5 min after stimulation (fig. 2B). These results demonstrate that
serum induces a time-dependent phosphorylation of p42/44MAPK and transient activation of
cPLA2. 
The Raf-MEK pathway is not the only pathway involved in EGF- and serum-induced
p42/44MAPK phosphorylation.
The results in figure 1 demonstrated that p42/44MAPK in quiescent or proliferating
cells is predominantly phosphorylated via the Raf-MEK pathway. In addition, Raf-MEK in
growth factor-stimulated cells is activated through p21ras, subsequently resulting in
p42/44MAPK activation (Haystead, et al., 1992; Marshall, 1995; Avruch et al., 1994). To
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investigate whether this is also true for EGF- and serum-stimulated Her14 cells, experiments
were performed using PD098059. As shown on the western blot of figure 3 (lanes 1 and 5),
p42/44MAPK is phosphorylated to a low level in quiescent cells, which has almost completely
disappeared in quiescent cells treated with PD098059 (lanes 2 and 6). Addition of serum (15
min) or EGF (15 min) to quiescent cells resulted in a strong increase in p42/44MAPK
phosphorylation (lanes 3 and 7, respectively). Next, the Raf-MEK pathway was inhibited by
treatment of the cells with PD098059 prior to stimulation with serum or EGF. The
phosphorylation of p42/44MAPK was largely reduced in serum-activated cells (lane 4) but
was hardly decreased in EGF-stimulated cells (lane 8). 
Taken together, these results indicate that EGF-induced p42/44MAPK
phosphorylation is mainly activated by other pathways than through Raf-MEK while in
serum-stimulated cells p42/44MAPK is partly phosphorylated via the Raf-MEK pathway and
partly through other signal transduction pathways. 
Involvement of Raf-MEK, PI3 kinase and PKC in p42/44MAPK phosphorylation.
In previous studies it was demonstrated that p42/44MAPK can be phosphorylated, in
addition to the Raf-MEK pathway, through other well-known signal transduction pathways,
including phosphatidylinositol-3-kinase (PI3K) (Bondeva et al., 1998) and protein kinase C
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Figure 2. Time course of serum-stimulated Her14 cells. Quiescent Her14 cells were stimulated with
5% serum for the indicated time periods. Thereafter, cells were harvested and p42/44MAPK
phosphorylation was detected on western blot (A) and cPLA2 activity was measured (B). A
representative experiment and S. D. are shown of three independent ones.
(PKC) (Romanelli & van de Werve, 1997). In order to establish whether these signal
transduction pathways are involved in serum- and EGF-induced p42/44MAPK
phosphorylation in Her14 fibroblasts, the effect of various inhibitors of these pathways was
investigated. The possible involvement of PI3K in the phosphorylation of p42/44MAPK was
examined using the inhibitors wortmannin and LY294002. Treatment of quiescent cells (fig.
4A, lanes 1 and 5) with wortmannin or LY294002 for 30 min prior to addition of serum
(lanes 3 and 4, respectively) or EGF (lanes 7 and 8, respectively) did not result in a
significant inhibition of phosphorylated p42/44MAPK as compared to cells stimulated with
serum or EGF alone (lanes 2 and 6, respectively). To ensure that wortmannin and LY294002
work in Her14 cells, the phosphorylation of the downstream PI3K enzyme protein kinase B
(PKB) was analysed on western blot. No phosphorylation of PKB was observed in the
presence of wortmannin or LY294002 (data not shown), as has been demonstrated also in
other cell lines (Burgering & Coffer, 1995; Alessi et al., 1996; Berra et al., 1998). These
results indicate that PI3K does not play a significant role in serum- or EGF-stimulated
phosphorylation of p42/44MAPK in Her14 cells.
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Figure 3. Effect of PD098059 pre-treatment on EGF- and serum-induced p42/44MAPK
phosphorylation in Her14 cells. Quiescent cells were left untreated (-s), incubated with PD098059
(pd) for 1h, stimulated afterwards with serum (+s) or EGF (egf), or the cells were treated with
PD098059 for 1h prior to stimulation with serum or EGF. The upper panel shows the phosphorylated
p42/44MAPK of serum-stimulated cells, and the lower panel of EGF-stimulated cells. Results shown are
representative of at least five independent experiments.
PKC activation in stimulated cells was prevented by treatment with the inhibitors:
Ro31-8220, a specific common PKC inhibitor (Newby et al., 1995), Gö6983 which inhibits
PKCα, βI, βII, δ and ζ isoforms (Gschwendt et al., 1996), and staurosporine known to inhibit
all PKCs and some other kinases (Couldwell et al., 1994). Figure 4B shows that p42/44MAPK
was phosphorylated to a low extent in quiescent cells (lanes 1 and 8) which was strongly
increased upon stimulation of serum (lane 2) or EGF (lane 9). Incubation of the cells with
PD098059 prior to addition of serum, resulted in a considerable reduction in p42/44MAPK
phosphorylation (lane 3) but only to a minor reduction in EGF-activated cells (lane 10),
which is in agreement with the results presented in figure 3. Pre-treatment of quiescent
Her14 cells with staurosporine or Ro31-8220 severely diminished p42/44MAPK
phosphorylation upon activation of the cells with either serum (lanes 4 and 5, respectively)
or EGF (lanes 11 and 12, respectively). However, Gö6983 treatment did not seem to have
any effect on the phosphorylation neither in serum- nor in EGF-stimulated cells (lanes 6 and
13, respectively). 
In addition, PKC down-regulation using phorbol ester (PdBu) treatment for 24h
was used to investigate the involvement of the conventional (α, βI, βII, γ) and novel (δ, ε, η,
µ, θ) PKCs. NIH3T3 fibroblasts, which are the parental cells of Her14 cells, express PKCα,
δ, ζ and λ (Mischak et al., 1993; Akimoto et al., 1994; Doornbos et al., 2000). The down-
regulation was confirmed by the absence of PKCα and δ on western blot (data not shown),
as was also demonstrated in other cell types (Kramer & Simon, 1999; Huwiler et al., 1993).
As shown in figure 4B (lanes 7 and 14), PKC down-modulation had only a slight effect on
p42/44MAPK phosphorylation induced by serum or EGF, indicating that the conventional and
novel PKCs seem to play a minor role in the signal transduction cascade leading to the
phosphorylation of p42/44MAPK. Furthermore, the differences in p42/44MAPK
phosphorylation were not due to variations in protein expression levels since p42MAPK was
present equally in all lanes (fig. 4B). 
Collectively, these data demonstrate that in both serum- and EGF-activated cells
p42/44MAPK phosphorylation is mediated via the Raf-MEK pathway and through PKC or a
(un)related kinase, that depends on the specificity of Ro31-8220. Furthermore, these data
suggest that Ro31-8220- or staurosporine-, but not Gö6983-dependent PKC isoforms are
involved in the activation of p42/44MAPK in serum- or EGF-stimulated Her14 cells. Also no
conventional or novel PKC isoforms are involved in the phosphorylation of p42/44MAPK
since down-regulation of these isozymes did not result in a reduced phosphorylation.
Although staurosporine is not a specific PKC inhibitor, the results obtained were similar to
those observed with the specific PKC inhibitor Ro31-8220, suggesting that staurosporine in
Her14 cells can be used to inactivate PKC. Furthermore, in serum-stimulated cells the Raf-
MEK pathway is more important while, in contrast, PKC or a (un)related kinase is more
important in EGF-stimulated cells.
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Figure 4. Phosphorylation of p42/44MAPK in the presence of inhibitors for PI3K (A) and PKC in
serum- (B, upper panel) and EGF-stimulated cells (B, lower panel). Quiescent cells (-s) were pre-
treated for 30 min with wortmannin (wt), LY294002 (ly), staurosporine (sta), Ro31-8220 (ro), or
Gö6983 (go), 1h with PD098059 (pd), or for 24h with PdBu (dr). Thereafter, the cells were stimulated
with serum (+s) or EGF (egf) for 15 min and p42/44MAPK phosphorylation and p42MAPK expression
(B) were detected on western blot. Results shown are representative of four independent experiments.
cPLA2 activity is increased by p42/44
MAPK that is phosphorylated via Raf-MEK and
through PKC.
The next objective was to investigate whether PKC and Raf-MEK are the two
major pathways leading to p42/44MAPK phosphorylation and subsequently to cPLA2
activation. Figure 5A shows a relatively low phosphorylation of p42/44MAPK in quiescent
cells (lanes 1 and 7) that was strongly increased in serum- (lane 2) and EGF- stimulated cells
(lane 8). As shown earlier a remarkable reduction in p42/44MAPK phosphorylation was
observed in quiescent cells treated with PD098059 prior to serum stimulation (lane 3) while
only a small reduction was observed in EGF-activated cells (lane 9). However, co-treatment
of quiescent cells with PD098059 plus Ro31-8220 either prior to serum (lane 4) or EGF
(lane 10) stimulation resulted in a complete inhibition of p42/44MAPK phosphorylation. The
involvement of the Raf-MEK pathway and PKC in the phosphorylation of p42/44MAPK was
further investigated by down-regulation of PKC, followed by incubation for one hour with
PD098059. This treatment did not result in an activation of p42/44MAPK (lanes 5 and 11)
indicating that with this treatment no other pathways are induced that activate p42/44MAPK.
Next, the phosphorylation of p42/44MAPK in these cells stimulated with serum or EGF was
analysed, still demonstrating the presence of some phosphorylated p42/44MAPK, although to
a lesser extent in serum- (lane 6) as compared to EGF-stimulated cells (lane 12). This
remaining phosphorylation is most likely due to activated PKC, or a (un)related kinase,
since these can not be down-regulated. Treatment of both PD098059 and staurosporine prior
to stimulation did not result in a phosphorylation of p42/44MAPK, demonstrating only the
involvement of the Raf-MEK pathway and PKC, or a (un)related kinase, in serum- or EGF-
induced p42/44MAPK phosphorylation. However, PKC, or a (un)related kinase, seems to play
a more important role in EGF- compared to serum-stimulated cells. These results are in
accordance with the results shown in figure 4.
cPLA2 activity was increased 1.8 in serum- (fig. 5B, column 2) and 2.1 fold in
EGF-activated cells (column 8) as compared to the activity in quiescent cells (columns 1 and
7). Inhibition of the Raf-MEK pathway by pre-treating the cells with PD098059 resulted in
a complete inhibition of cPLA2 activity in serum- (column 3), but only to a partial inhibition
in EGF-activated cells (column 9). Even a further decrease in activity was measured in
PD098059 plus Ro31-8220 treated cells, which was more pronounced in EGF- (column 10)
than in serum-stimulated cells (column 4). These results demonstrate that cPLA2 activity is
mediated via the Raf-MEK pathway and through PKC, or a (un)related kinase, in serum-
and EGF-activated cells. Down-regulation of PKC followed by an incubation with
PD098059, prior to serum (column 6) or EGF (column 12) stimulation, resulted in an
activity of cPLA2 which was found to be at the level that is present in quiescent (columns 1
and 7) and down-regulated plus PD098059 treated cells (column 5 and 11). However, the
activity was higher as in PD098059 plus Ro31-8220 treated cells. 
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Taken together cPLA2 activity in serum-activated cells is regulated for the greater
part via the Raf-MEK pathway and for a minor part through PKC, or a (un)related kinase,
while in EGF-stimulated cells cPLA2 is predominantly regulated via PKC, or a (un)related
kinase, and to a much lesser extent through Raf-MEK. Correspondingly, p42/44MAPK is
activated via the same pathways as cPLA2 is, thus demonstrating a relation between
p42/44MAPK phosphorylation in serum- and EGF-activated Her14 cells and cPLA2 activity.
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Figure 5. Inhibition of both PKC and the Raf-MEK pathway prohibits p42/44MAPK
phosphorylation, and decreases cPLA2 activity at the same time in serum- and EGF-stimulated
Her14 cells. p42/44MAPK phosphorylation (A) and cPLA2 activity (B) were determined of quiescent
cells treated with vehicle (-s), pre-treated for 1h with PD098059 (pd), 1h PD098059 and 30 min Ro31-
8220 (ro), or treated for 24h with PdBu (dr) followed by a 1h incubation with PD098059, and
thereafter stimulated with either serum (+s) or EGF (egf). Results and S. D. for cPLA2 activity are
shown of two independent experiments. 
PKC activates p42/44MAPK through MEK.
It has been reported that PKC is able to activate p42/44MAPK directly (Grammer
& Blenis, 1997), through MEK (Grammer & Blenis, 1997), or via Raf-MEK (Adomeit et
al., 1999; Sozeri et al., 1992). The latter pathway does not occur in our cells since
PD098059 did not inhibit serum- or EGF-induced p42/44MAPK phosphorylation completely.
In order to establish the pathway in which PKC, or a (un)related kinase, phosphorylates
p42/44MAPK, quiescent cells were treated either with PD098059 alone or treated with
PD098059 and thereafter stimulated with serum or EGF. The phosphorylation of
p42/44MAPK was detected on western blot (fig. 6A), showing no phosphorylation in the
presence of PD098059 (lane 4). In cells incubated with PD098059 prior to addition of serum
,some phosphorylation was present (lane 3) which was, as shown earlier, remarkably higher
in EGF-stimulated cells (lane 5). Inhibiting MEK activity by incubating the cells with
U0126 for 1h prior to stimulation resulted in a complete loss of phosphorylated p42/44MAPK
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Figure 6. Effect of PD098059 and U0126 on the phosphorylation of p42/44MAPK and MEK1/2 in
serum- and EGF-activated cells. Quiescent cells were treated with PD098059 (pd), U0126 (u), or
both for 1h and thereafter stimulated with serum or EGF. Cell lysates were separated on gel and (A)
p42/44MAPK phosphorylation, (B) p42MAPK expression, (C) MEK1/2 phosphorylation and (D) MEK-1
expression were analysed on western blot as described in Materials and Methods. Results shown are
representative of three independent experiments.
(fig. 6A, lanes 2 and 6). The same result was obtained in cells treated with both PD098059
plus U0126 before addition of serum or EGF (lanes 1 and 7, respectively). p42MAPK
expression on western blot showed no significant differences in the protein expression level
(fig. 6B, lanes 1-7). These results demonstrate that PKC does not phosphorylate p42/44MAPK
directly since a combined treatment of PD098059 and U0126 prior to serum or EGF
stimulation did not result in phosphorylation of p42/44MAPK. In addition, MEK1/2
phosphorylation was detected on western blot using an antibody directed against
phosphorylated MEK-1 and 2 (fig. 6C). The levels of MEK1/2 phosphorylation were
comparable in serum- as well as in EGF-stimulated cells pre-treated with PD098059 (lanes
3 and 5, respectively), U0126 (lanes 2 and 6, respectively) and PD098059 plus U0126 (lanes
1 and 7, respectively). Furthermore, these levels were higher compared to quiescent cells
treated with PD098059 alone (lane 4). MEK-1 protein expression levels were comparable
in all samples (fig. 6D, lanes 1-7), showing that differences observed in MEK
phosphorylation were not due to a change in the protein expression levels. These data
demonstrate that PKC, or a (un)related kinase, phosphorylates p42/44MAPK through MEK,
since U0126 inhibits p42/44MAPK but not MEK phosphorylation in serum- and EGF-
activated cells.
Phorbol ester-induced PKC activation subsequently activates p42/44MAPK but not cPLA2.
Since PKC plays a role in the activation of p42/44MAPK in serum- and EGF-
stimulated cells that subsequently results in cPLA2 activity, we explored whether the same
results could be obtained when PKC was activated directly with phorbol ester. Therefore,
quiescent Her14 cells were incubated with PdBu for 15 min resulting in a strong increase in
the phosphorylation of p42/44MAPK on western blot (fig. 7A lane 2) compared to non-treated
cells (lane 1). Pre-incubation of the cells with PD098059 caused a strong decrease in PdBu-
induced p42/44MAPK phosphorylation (lane 3), which was completely inhibited upon U0126
treatment (lane 4). Next, the PdBu activation of PKC was inhibited by a pre-treatment of the
cells for 30 min with the PKC inhibitors staurosporine, Ro31-8220, Gö6983 (PKCα, βI, βII,
δ and ζ) or Gö6976 (PKCα, βI, and µ) (Wenzel-Seifert et al., 1994). Figure 7A shows a
complete inhibition of p42/44MAPK phosphorylation in cells pre-treated with staurosporine,
Ro31-8220 and Gö6983 (lanes 5, 6 and 7, respectively) but a partial decrease in
phosphorylation upon Gö6976 incubation (lane 8). These data indicate that activation of
PKC by PdBu results in the phosphorylation of p42/44MAPK which is partially mediated
through Raf-MEK and partially proceeds through MEK. Furthermore, this activation of
p42/44MAPK is mediated through Gö6983 and partially through Gö6976 dependent PKC
isoforms.
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In order to correlate PdBu-induced p42/44MAPK phosphorylation with cPLA2
activity, the activity was measured in homogenates of quiescent cells and cells that were
stimulated afterwards with PdBu. Hardly any increase in cPLA2 activity was observed in
stimulated (fig. 7B column 2) compared to unstimulated cells (fig. 7B column 1). Addition
of PdBu to cells treated with PD098059 did not result in a decrease in cPLA2 activity (fig.
7B column 3) and a slight decrease to basal level in U0126 treated cells (fig. 7B column 4).
Also no significant decreases in cPLA2 activity were observed in cells incubated with the
different PKC inhibitors prior to stimulation with PdBu (fig. 7B columns 5-8), except for a
slight decrease in activity in the presence of Ro31-8220. In conclusion, PdBu-induced PKC
activation results in the phosphorylation of p42/44MAPK that partially proceeds through
MEK and via Raf-MEK but which does not lead to cPLA2 activation. 
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Figure 7. Phorbol ester-induced activation of p42/44MAPK and cPLA2. Quiescent cells (-s) were
pre-treated for 1h with PD098059 (pd) or U0126 (u), or for 30 min with staurosporine (sta), Ro31-
8220 (ro), Gö6983 (go6983), or Gö6976 (go6976). Thereafter, the cells were stimulated with PdBu
(pdbu) for 15 min. p42/44MAPK phosphorylation was analysed on western blot (A) and cPLA2 activity
was measured (B) as described in Materials and Methods. Results shown are representative of two
independent experiments with S. D. shown for cPLA2 activity.
Discussion
We show here that p42/44MAPK in both quiescent and proliferating cells is
predominantly phosphorylated via the Raf-MEK pathway since PD098059 treatment almost
completely inhibited this phosphorylation (fig. 1A, C). However, the p42/44MAPK
phosphorylation only corresponded with cPLA2 activity in quiescent cells. PD098059 and
U0126 did not reduce cPLA2 activity in proliferating cells, suggesting that other signal
transduction cascades regulate cPLA2 activity in these cells. For instance, p38
MAPK has been
shown to activate cPLA2 in platelets, (Kramer, et al., 1996; Hefner, et al., 2000) and c-Jun
NH2-terminal kinase has been implicated to activate cPLA2 in astrocytes (Hernández et al.,
1999). 
cPLA2 activity was found to be slightly higher in quiescent than in proliferating
cells. This is surprising since one would expect the activity in proliferating cells to be higher.
All the more because p42/44MAPK was phosphorylated to a higher extent in proliferating
cells. This might imply that only a very small fraction of the phosphorylated p42/44MAPK
accounts for the cPLA2 activation as measured in quiescent cells. In addition, it has been
shown in vitro that cPLA2 losses its catalytic activity prematurely when acting on vesicles
containing phospholipid substrate (Witmer et al., 1995; Bayburt & Gelb, 1997; Burke et al.,
1999). Although, the precise mechanism for this inactivation is not yet established it might
explain why cPLA2 activity is lower in proliferating than in quiescent cells. Furthermore, in
quiescent cells treated with U0126, cPLA2 was found to be still active although p42/44
MAPK
phosphorylation was not detected anymore. This remainder is the, so called, basal activity
of cPLA2 because treatment with alkaline phosphatase did not reduce this activity
(Schalkwijk, et al., 1995).
In contrast to the activation of p42/44MAPK in quiescent and proliferating cells,
p42/44MAPK is not solely phosphorylated via the Raf-MEK pathway in EGF- and serum-
stimulated Her14 cells. This is because PD098059 pre-treatment did not completely inhibit
p42/44MAPK phosphorylation in serum-activated cells, and did not seem to have a big effect
at all in EGF-stimulated cells (fig. 3). However, PD098059 treatment does result in the
inhibition of the Raf-MEK pathway since p42/44MAPK phosphorylation in serum-activated
cells was decreased. In addition, it has been published that p42/44MAPK phosphorylation is
almost completely inhibited with PD098059 in hydrogen peroxide-stimulated Her14 cells
(van Rossum et al., 1999), indicating that no other signal transduction cascades are
influenced by this inhibitor. In addition, p38MAPK phosphorylation was not increased in
either EGF- or serum-stimulated cells as compared to unstimulated cells. cPLA2 activity in
cells treated with the p38MAPK inhibitor, SB203580, before EGF or serum stimulation did
not result in a significant reduction in cPLA2 activity compared to control cells (data not
shown). Although, this indicates that p38MAPK in Her14 cells is not involved in cPLA2
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activation, an involvement of other p38MAPK isoforms can not be excluded due to the
specificity of SB203580 (Cohen, 1997).
By the use of different inhibitors we have investigated whether known signal
transduction pathways including PI3K and PKC are involved in serum- or EGF-activated
p42/44MAPK and cPLA2 activity in Her14 cells. PI3K did not seem to play a significant role
in the phosphorylation of p42/44MAPK in serum- or EGF-stimulated cells since wortmannin
and LY294002 did not reduce p42/44MAPK phosphorylation (fig. 4A lanes 3, 4 and 7, 8).
Also Conway et al. (1999) showed that PI3K plays a minor role in EGF-activated
p42/44MAPK phosphorylation in airway smooth muscle cells while in PDGF-stimulated
Swiss 3T3 fibroblasts PI3K plays a role in both the early and the late response (Grammer &
Blenis, 1997).
The data presented here show that PKC, or a (un)related kinase, depending on the
specificity of Ro31-8220, plays a more important role in EGF- as in serum-induced
p42/44MAPK phosphorylation. This is supported by the findings that treatment with the
common PKC inhibitors Ro31-8220 and staurosporine resulted in a severe inhibition of
p42/44MAPK phosphorylation. In addition, Gö6983 dependent and phorbol ester sensitive
PKCs were not involved, since Gö6983 treatment and PKC down-regulation did not reduce
p42/44MAPK phosphorylation (fig. 4). However, Gö6983 only inhibit a few PKC isoforms in
contrast to Ro31-8220 and staurosporine, while prolonged phorbol ester treatment results in
the down-regulation of the conventional and novel PKC isotypes, leaving the atypical PKC
isotypes unaffected (Huwiler et al., 1992). In accordance with this is the presence of
phosphorylated p42/44MAPK in PKC down-regulated and PD098059 treated cells which is a
little elevated in EGF-activated compared to serum-stimulated cells. Furthermore, the
involvement of PKC, or a (un)related kinase, and the Raf-MEK pathway was also confirmed
by treatment of the cells with both PD098059 and Ro31-8220 prior to stimulation. 
We show that PKC, or a (un)related kinase, phosphorylates p42/44MAPK through
MEK, since PD098059 did not completely reduce the phosphorylation in contrast to U0126
(fig. 6). However, we cannot exclude the possibility that some part of the PKC signal
proceeds via Raf-MEK which has been previously reported (Kolch et al., 1993; van Dijk et
al., 1997). Moreover, activation of p42/44MAPK by PKC, or a (un)related kinase,
independent of either Raf or MEK was excluded because pre-incubation of the cells with
PD098059 and U0126 did not result in p42/44MAPK phosphorylation. Although, MEK was
phosphorylated and present to a similar level as in PD098059 and U0126 treated cells prior
to serum or EGF stimulation. Activation of p42/44MAPK through PKC-MEK has also been
observed in Swiss 3T3 fibroblasts stimulated with PDGF (Grammer & Blenis, 1997; Berra
et al., 1995), but this activation pathway leads to the prolonged activation of p42/44MAPK
while in the initial phase p42/44MAPK could be activated by PKC, independent of Raf or
MEK. This is not the case in Her14 fibroblasts, as inhibition of either PKC or a (un)related
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Figure 8. Models summarising the results in this paper for (A) quiescent (solid line) and
proliferating (dashed line), (B) EGF- (solid line) and serum- (dashed line) and (C) PdBu-
regulated p42/44MAPK and cPLA2 activation in Her14 fibroblasts. (A) Activation of p42/44
MAPK in
quiescent and proliferating cells proceeds through Raf-MEK leading to cPLA2 activation in the
quiescent but not in the proliferating cells. (B) EGF-induced cPLA2 activity is mediated through two
pathways: predominantly through PKC-MEK-MAPK and less via Raf-MEK-MAPK while in serum-
stimulated cells the signal is for the greater part transduced through Raf-MEK-MAPK and the smaller
part via PKC-MEK-MAPK both leading to cPLA2 activity. (C) PdBu-induced PKC activation leads to
p42/44MAPK phosphorylation that is partially mediated via MEK and through Raf-MEK but this does
not result in cPLA2 activation. italic: effective inhibitors 
kinase by Ro31-8220 or staurosporine or the Raf-MEK pathway by PD098059 prior to
stimulation for different periods of time did not result in a differential phosphorylation of
p42/44MAPK (data not shown). These data suggests that both pathways are activated at the
same time and converge to MEK to fully activate p42/44MAPK (see model in fig. 8). In
conclusion, the data clearly demonstrate that serum-induced p42/44MAPK phosphorylation is
mediated through PKC, or a (un)related kinase, but the majority of the signal proceeds
through the Raf-MEK pathway. Both PKC, or a (un)related kinase, and the Raf-MEK
pathway are involved in EGF-induced p42/44MAPK phosphorylation, although PKC plays a
more important role than the Raf-MEK pathway. 
In contrast to serum- or EGF-induced p42/44MAPK phosphorylation, which
involves the activation of PKC or a (un)related kinase, direct activation of PKC by phorbol
ester (PdBu) incubation resulted in yet another pathway. Direct activation of PKC resulted
clearly in the phosphorylation of p42/44MAPK through Raf-MEK and via MEK as shown by
the partial inhibition in the presence of PD098059 and a complete inhibition in the presence
of U0126 (fig. 7). Moreover, other PKC isoforms are involved in PdBu-stimulated
compared to serum- and EGF-activated cells, as Gö6983 completely abolished p42/44MAPK
phosphorylation in PdBu-activated cells while it did not had any effect upon serum or EGF
addition. 
As shown in the models (fig. 8), p42/44MAPK is differentially activated in serum-
and EGF- as well as in PdBu-stimulated cells, but also compared to quiescent and
proliferating cells. The presence and the level of phosphorylated p42/44MAPK in serum- or
EGF-activated cells corresponds with the activity of cPLA2 (fig. 5) as decreases in the level
of phosphorylated p42/44MAPK by inhibiting the Raf-MEK, PKC-MEK or both pathways
results in a decrease in cPLA2 activity. The data show that in cells stimulated with serum, in
which the Raf-MEK pathway plays a more important role than PKC, or a (un)related kinase,
in the phosphorylation of p42/44MAPK, cPLA2 activity was reduced in a similar manner. EGF
stimulation proceeds for the greater part through PKC, or a (un)related kinase, instead of
Raf-MEK, which is observed in the reduction of p42/44MAPK phosphorylation but also in the
subsequent cPLA2 activity. While p42/44
MAPK is activated via the same pathway only
cPLA2 activity corresponds with the presence of phosphorylated p42/44
MAPK in quiescent
but not in proliferating cells. Additionally the presence of p42/44MAPK phosphorylation and
cPLA2 activity were also not related in cells stimulated with PdBu (fig. 7). However, in cat
iris sphincter smooth muscle cells PdBu is able to induce an increase in arachidonic acid,
which is mediated by cPLA2 (Husain & Abdel-Latif, 1998). 
Collectively, these results imply the existence of different pools of p42/44MAPK that
have to be phosphorylated at the right time and location to activate cPLA2, unless U0126 is
not that specific in preventing p42/44MAPK. The existence of different pools has been
suggested for cPLA2. cPLA2 in Her14 fibroblasts was reported to be localised in clusters
64
Chapter 2
near the vicinity of all organellar membranes except for the golgi apparatus and the nucleus
(Bunt et al., 1997). Subsequently, it was shown that these clusters represent the inactive
form of cPLA2 from which active monomers can be recruited which might occur via
phosphorylation by p42/44MAPK (Bunt et al., 2000). Also p42/44MAPK phosphorylation has
been reported to occur at different locations induced by different agonists. In EGF-activated
cells the EGF receptor was still active when internalised to endosomes (Lai et al., 1989;
Wada et al., 1992), suggesting that the active receptor may continue transducing the signal.
This has been further stated by the compartimentalisation of phosphorylated EGF receptors
and a population of Shc proteins (Baass et al., 1995), and the presence of active Raf-1 and
MEK in the early endosomes of hepatocytes (Pol et al., 1998). However, no such
mechanism for signal transduction was observed in insulin-induced activation of its receptor
in liver parenchyma (Di Guglielmo et al., 1994). In conclusion, p42/44MAPK in quiescent or
proliferating cells are differentially activated as in cells stimulated either with serum, EGF
or PdBu probably because different pools of p42/44MAPK and cPLA2 are activated. 
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Abstract
Reactive oxygen species are involved in various cellular processes and
diseases. It has been suggested that reactive oxygen species function as mediators of
signal transduction, since they can mimic growth factor-induced signalling. H2O2 has
been reported to activate phospholipase A2 and hence we investigated the pathway by
which reactive oxygen species regulates cytosolic phospholipase A2 (cPLA2) activity in
Her14 fibroblasts. cPLA2 was activated by various concentrations of H2O2 in a rapid
and transient manner. Also cumene hydroperoxide induced cPLA2 activity. H2O2
stimulation of Her14 cells resulted in a partial phosphorylation of cPLA2, which was
mediated through the Raf-MEK-p42/44MAPK pathway. Besides, cPLA2 was partially
activated through a phosphorylation-independent mechanism. Translocation of cPLA2
to the membrane fraction occurred in H2O2-stimulated cells, with a concomitant
increase in cPLA2 activity which could not be decreased by removing calcium. Since
cPLA2 phosphorylation has to precede its calcium-dependent translocation to
membranes, and since H2O2 can peroxidise phospholipids resulting in enhanced cPLA2
activity, we suggest that the phosphorylation-independent increase in cPLA2 activity
might be due to peroxidation of phospholipids.
Introduction
Most mammalian cells generate reactive oxygen species (ROS) upon stimulation
with various ligands, including cytokines, growth factors and hormones (Lo & Cruz, 1995;
Sundaresan et al., 1995; Meier et al., 1989). ROS comprises a variety of oxygen free
radicals, including superoxide anions, hydroxyl radicals, hydrogen peroxide and nitric
oxide. ROS can lead to oxidative stress that has been implicated in cellular processes, such
as proliferation (Rao & Berk, 1992; Irani et al., 1997), apoptosis (Buttke & Sandstrom,
1994; Jacobson, 1996; Polyak et al., 1997), but also cellular injury (Chen et al., 1996;
Sapirstein et al., 1996) and diseases, such as atherosclerosis and neuronal degenerative
diseases (Crawford & Blankenhorn, 1991; Schubert et al., 1995). It has been suggested that
ROS may function as mediators of signal transduction processes (Sundaresan, et al., 1995;
Chen et al., 1995). Additionally, exogenous administration of hydrogen peroxide (H2O2)
induced phosphorylation of the epidermal growth factor (EGF) and platelet-derived growth
factor (PDGF) receptor (Miller et al., 1994; Gamou & Shimizu, 1995), suggesting that
oxygen free radicals mimic growth factor-induced signalling events. Indeed H2O2-induced
tyrosine phosphorylation of the EGF receptor resulted in complex formation with the
signalling molecules Shc, Grb2 and sos followed by ras activation in vascular smooth
muscle cells (VSMC) (Rao, 1996). Although H2O2 was shown to inhibit EGF receptor
internalisation and ubiquitination (de Wit et al., 2001), this does not necessarily contradict
a role of ROS in growth factor-mediated signalling. Furthermore, oxidative stress was
shown to induce Raf-1 activation (Kasid et al., 1996; Abe et al., 1998) and activation of
p42/44MAPK as well as the c-Jun NH2-terminal kinase (JNK) (Stevenson et al., 1994;
Sundaresan, et al., 1995; Guyton et al., 1996), p38MAPK (Buschbeck et al., 1999) and PKC
family members (Konishi et al., 1997). ROS were also able to increase the expression of
cyclin D and the immediate early genes c-fos and c-jun (Naveilhan et al., 1994; Martínez-
Muñoz et al., 2001). It has been suggested that phospholipase A2 (PLA2) could be involved
in these events, since a non-specific PLA2 inhibitor, mepacrine, blocked H2O2-induced c-fos
and c-jun mRNA expression in VSMC (Rao et al., 1993; Rao et al., 1993). Also, PLA2 and
ROS have been implicated in cellular injury (Weinberg, 1991; Bonventre, 1993). Moreover,
in vitro studies showed that the presence of peroxidated phospholipids in substrate vesicles
enhanced PLA2 activity and the subsequent release of arachidonic acid (Rashba-Step et al.,
1997; Chaitidis et al., 1998).
The 85-kDa cytosolic PLA2 (cPLA2) preferentially generates the oxidant sensitive
arachidonic acid from membrane phospholipids and both calcium and phosphorylation
regulate its activity. Submicromolar concentrations of calcium are required for cPLA2 to
translocate from the cytosol to the membrane, where its substrate is located, and this
translocation is mediated by its calcium-dependent phospholipid binding domain (Nalefski
et al., 1994). Phosphorylation of cPLA2 has been shown to occur through p42/44
MAPK (Lin
et al., 1993; Qiu & Leslie, 1994; van Rossum et al., 2001), p38MAPK (Kramer et al., 1996;
Börsch-Haubold et al., 1998) and JNK (Hernández et al., 1999; van Putten et al., 2001).
Moreover, cPLA2 is maximally activated when it is first phosphorylated followed by a
calcium-dependent translocation to membranes (Abdullah et al., 1995; Schalkwijk et al.,
1996). The purpose of the present study was, to examine whether H2O2 is able to activate
cPLA2 in Her14 fibroblasts and, more importantly, to determine the pathway through which
cPLA2 is activated. It is demonstrated that cPLA2 is activated by various concentrations of
H2O2 and cumene hydroperoxide. H2O2 induced a transient activation of cPLA2. cPLA2 was
partially activated by phosphorylation through the Raf-MEK-p42/44MAPK pathway, and
partially through a phosphorylation-independent mechanism. H2O2 can peroxidise
phospholipids thereby enhancing cPLA2 activity, that might be responsible for the
phosphorylation-independent increase in cPLA2 activity, since cPLA2 translocated to the
membrane fraction under calcium free conditions, which resulted in an increased cPLA2
activity.
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Materials and Methods
Materials.
Tissue culture nutrients, Dulbeccos modified Eagles medium (DMEM) and foetal
bovine serum (FBS) were purchased from Gibco BRL (Scotland). PD098059 and U0126
were obtained from Biomol (Playmouth meeting, USA) and Promega (Madison, USA),
respectively. Protifar was from Nutricia (Zoetermeer, The Netherlands) and alkaline
phosphatase was from Roche diagnostics (Mannheim, Germany). Hydrogen peroxide,
cumene hydroperoxide and dipalmitoylglycerol were purchased from Sigma (Steinheim,
Germany). 1-Stearoyl-2-[1-14C]arachidonoyl-glycero-3-phosphocholine was obtained from
Amersham (Buckinghamshire, England).  All other chemicals were either from Sigma or
Merck (Darmstadt, Germany). 
Cell culture and stimulation.
Her14 cells, which are mouse NIH3T3(0) fibroblasts transfected with the human
EGF-receptor cDNA, were grown in DMEM supplemented with 7.5% FBS. Cells were
maintained at 37°C in a humidified atmosphere. Cells were grown to a confluency of 30,000
cells/cm2, whereafter they were serum-starved overnight. After washing the cells twice with
phosphate buffered saline (PBS), the cells were incubated for the indicated periods in PBS
supplemented with 5 mM glucose in the absence or presence of the indicated concentrations
hydrogen peroxide (H2O2) at 37°C. The same procedure was performed for cells stimulated
with cumene hydroperoxide. When appropriate, the cells were treated with PD098059 (50
µM) or U0126 (50 µM) 1 h prior to stimulation to inhibit MEK activity. 
Cell lysis and cell fractionation.
After stimulation, the cells were washed twice with ice-cold PBS whereafter the
cells were scraped in homogenisation buffer (50 mM Hepes/NaOH pH 7.4, 0.25 M sucrose,
50 mM NaF, 250 µM Na3VO4, 1 mM EGTA, 10 µM leupeptin, 1 µM pepstatin and 1 mM
PMSF). The cells were homogenised by 15 strokes through a 26G-needle and sonicated for
3 times 10 seconds. The amount of protein was measured according to Bradford (1976)
using a Bio Rad novapathTM microplate reader. Alternatively, the homogenate was
centrifuged at 200,000xg for 30 min at 4°C to obtain the membrane fraction and the
cytosolic fraction.
Western blot analysis.
Cell homogenates (10 µg protein) were separated on 10% SDS-PAGE and
transferred to polyvinylidene difluoride membrane by semi-dry blotting using a BioRad
trans-blot SD. The membrane was blocked for 1h at RT with 2% milkpowder in PBST (PBS
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containing 0.1% (v/v) Tween-20), followed by primary antibody incubations for 1h at RT in
0.2% milkpowder in PBST. Phosphorylated p42/44MAPK was detected with a phospho-
p42/44MAPK rabbit polyclonal antibody at a dilution of 1:1000 (New England Biolabs
Incorporated, Beverly, MA). ERK2 (0.5 µg/ml) and cPLA2 (0.2 µg/ml) were detected with
a monoclonal antibody from Transduction Laboratories (Lexington, KY) or from Santa Cruz
Biotechnology (Heidelberg, Germany). Then, the membrane was washed and primary
antibodies were detected with goat anti-rabbit or rabbit anti-mouse IgG conjugated to
horseradish peroxidase and the bands were visualised with enhanced chemiluminescence
(NENTM, Life science products, Boston).
cPLA2 activity assay.
cPLA2 activity was measured by the release of radiolabeled arachidonic acid from
the sn-2 position of 1-stearoyl-2-[1-14C]arachidonoyl-glycero-3-phosphocholine as
described previously (Schalkwijk, et al., 1996). The radiolabeled phosphatidylcholine was
dried under N2 together with dipalmitoylglycerol and then dispersed in water by sonification
for 4 times 15 s under nitrogen to give final concentrations of 4 and 2 µM, respectively. The
assay incubation mixture contained 0.2 M Tris pH 8.5, 1 mM CaCl2, 5 mM DTT and 10 µg
cell homogenate in a total volume of 200 µl. After incubation for 7-10 min at 37°C the
released radiolabeled arachidonic acid was extracted by a modified Dole extraction
procedure (van den Bosch et al., 1974) and the radioactivity was determined in a
scintillation counter (Tri-Carb 15000, Packard, Meriden, USA). In this way only the activity
of cPLA2 was measured (Spaargaren et al., 1992; Atsumi et al., 1998) and always less than
5% of the substrate was hydrolysed. Measuring the activity of non-phosphorylated cPLA2
was performed as described previously (Schalkwijk et al., 1995) by addition of 10 units
alkaline phosphatase to an assay mixture containing 10 µg homogenate, 1 mM MgCl2, 0.25
M Tris pH 8.5, 1.25 mM CaCl2 and 6.25 mM DTT in a final volume of 160 µl. After a 20
min incubation at 37°C, 40 µl substrate was added and the cPLA2 activity assay was
performed as described above. 
Results
H2O2 induces activation of cPLA2.
In order to investigate whether cPLA2 is activated by oxidative stress, quiescent
Her14 cells were stimulated with different concentrations H2O2 for 10 min. The cells were
subsequently harvested and cPLA2 activity was measured as described in Materials and
Methods. Figure 1A shows that H2O2 is able to increase cPLA2 activity dose dependently,
1.6-2 fold, being maximal around 2 mM H2O2. The effect of H2O2 on cell integrity was
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determined by the release of lactate dehydrogenase (LDH). Exposure of Her14 cells with
increasing concentrations of H2O2 up to 10 mM did not result in a significant release of LDH
as compared to control cells which was shown previously (de Wit et al., 2000). Next, we
established whether cPLA2 can be activated by another oxidant, which has different
molecular and physicochemical properties than H2O2. Therefore, quiescent Her14 cells were
treated with different concentrations of cumene hydroperoxide for 10 min. This resulted in
a similar activation pattern of cPLA2 to that observed with H2O2, being dose dependent and
maximally activated around 1 mM (fig. 1B). 
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Figure 1. Concentration-dependent activation of cPLA2 by (A) H2O2 and (B) cumene
hydroperoxide. Quiescent Her14 cells were stimulated for 10 min with different concentrations of (A)
H2O2 or (B) cumene hydroperoxide. Thereafter, the cells were harvested and cPLA2 activity was
measured as described in Materials and Methods. A representative experiment ± S. D. are shown of,
respectively, 3 and 2 independent experiments.
Subsequently, the time course of cPLA2 activation induced by 1 mM H2O2 was
examined. H2O2 induced a rapid activation of cPLA2 within 5 min after stimulation, which
appears to be transient, reaching near basal levels again after 60 min of H2O2 stimulation
(fig. 2). These data show that cPLA2 in Her14 fibroblasts was transiently activated by
different concentrations of oxidative stress and in a time-dependent manner.
Regulation of cPLA2 activity in H2O2-stimulated Her14 fibroblasts.
We recently showed in Her14 cells stimulated with EGF or serum that p42/44MAPK
was activated via Raf-MEK and through PKC-MEK, subsequently leading to cPLA2
activation (van Rossum et al., 2001). H2O2 has also been demonstrated to induce activation
of p42/44MAPK (Rao, 1996; Abe, et al., 1998; de Wit et al., 1998) and hence we investigated
the possible involvement of p42/44MAPK in H2O2-induced cPLA2 activation. Figure 3A (left
columns) shows in quiescent cells treated for 5 and 30 min with H2O2 an increase in cPLA2
activity of about 2 and 1.5 fold respectively, as compared to control cells, which is in
agreement with the results shown in figure 2. H2O2 stimulation for 5 and 30 min of cells pre-
treated for 1h with the MAPK kinase (MEK) inhibitor PD098059 resulted in an inhibition
of cPLA2 activity (fig. 3A, middle columns) to the level present in quiescent cells.
PD098059 binds directly to the non-phosphorylated isoforms of MEK (MEK-1 and 2),
thereby preventing their Raf-mediated activation (Dudley et al., 1995; Favata et al., 1998).
However, cPLA2 activity was even further decreased in quiescent cells incubated with
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Figure 2. Time course of H2O2-stimulated Her14 cells. Quiescent Her14 cells were stimulated for
the indicated times with 1 mM H2O2 whereafter, the cells were harvested and cPLA2 activity was
measured as described in Materials and Methods. Data are shown as means ± S. D. (n=2).
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PD098059 compared to untreated cells. Similar results were obtained with another MEK
inhibitor (fig. 3A, right columns), U0126, that inhibits the catalytic activity of MEK (Favata,
et al., 1998). These data indicate that H2O2 activates cPLA2 via the Raf-MEK-p42/44
MAPK
pathway in Her14 fibroblasts. 
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Figure 3. Effect of the MEK inhibitors, PD098059 and U0126, on (A) cPLA2 activity and (B)
p42/44MAPK phosphorylation in H2O2-stimulated Her14 cells. Quiescent Her14 cells were left
untreated, incubated for 1h with PD098059 or U0126 and then stimulated for 5 and 30 min with H2O2.
(A) Cell lysates were prepared in which cPLA2 activity was measured and (B) p42/44
MAPK
phosphorylation and p42MAPK expression were analysed on western blot as described in Materials and
Methods. Results shown are representative of 2 independent experiments
However, we have recently demonstrated that inhibiting the phosphorylation of
p42/44MAPK did not always lead to a reduced cPLA2 activity (van Rossum, et al., 2001).
Therefore, the phosphorylation of p42/44MAPK in the same samples was analysed on western
blot, showing phosphorylated p42/44MAPK in quiescent cells (fig. 3B, lane 1) which is
increased upon H2O2 stimulation, and is significantly higher after 5 min (lane 2) than after
30 min (lane 3). This is in line with the cPLA2 activity measured (fig. 3A, left columns) in
these cells. No, p42/44MAPK phosphorylation was present in quiescent cells treated with
PD098059 (lane 4), as in cells stimulated afterwards for 5 min with H2O2 (lane 5). However,
at 30 min, p42/44MAPK phosphorylation was present again (lane 6), which has to be due to
a pathway independent of Raf-MEK. p42/44MAPK phosphorylation was not detectable in
quiescent cells treated with U0126 (lane 7) as well as in cells stimulated afterwards with
H2O2 for 5 or 30 min (lanes 8, 9, respectively). p42
MAPK levels were analysed on western
blot showing that p42MAPK was present in equal amounts in all samples. Taken together,
these results show activation of p42/44MAPK via the Raf-MEK pathway in quiescent cells
that correlated with cPLA2 activity and which both can be decreased by PD098059
treatment. However, H2O2-induced cPLA2 activation is only partially mediated by
p42/44MAPK, because both PD098059 and U0126 were unable to completely inhibit the
increased cPLA2 activity. p42/44
MAPK phosphorylation in H2O2-stimulated cells is activated
via the Raf-MEK pathway, and in addition, a secondary response in p42/44MAPK activation
occurs through a Raf-MEK-independent pathway.
cPLA2 activation induced by H2O2 is partially independent of its phosphorylation.
From figure 3A it is concluded that H2O2-induced cPLA2 activity is not completely
mediated by p42/44MAPK. This could be mediated by one of the other MAPK family
members, since JNK in astrocytes and p38MAPK in platelets have been shown to
phosphorylate and activate cPLA2 (Kramer, et al., 1996; Hernández, et al., 1999; van Putten,
et al., 2001; Börsch-Haubold, et al., 1998). Therefore, Her14 cells were stimulated either
with EGF or with H2O2 and cPLA2 activity was measured showing an increase in cPLA2
activity as compared to unstimulated cells (fig. 4). To evaluate whether the increase in
cPLA2 activity was entirely due to phosphorylation of the enzyme, the homogenates were
incubated with alkaline phosphatase, whereafter cPLA2 activity was measured. This
treatment revealed a complete reduction to basal level of cPLA2 activity in EGF-stimulated
cells (fig. 4), as has been demonstrated previously (Schalkwijk, et al., 1995). However, no
complete reduction was measured in H2O2-stimulated cells, suggesting that, in addition to
phosphorylation, cPLA2 was activated by another mechanism. 
It has been shown in vivo that ROS can peroxidise phospholipids (Davies, 1995;
Drummen et al., 1999). cPLA2 activity was shown to be increased when vesicles containing
peroxidised phospholipids were used as a substrate. In these experiments, also the calcium
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requirement for cPLA2 was decreased (Rashba-Step, et al., 1997). To determine whether
H2O2 treatment of the cells resulted in an increased, calcium-independent, translocation of
cPLA2 to cellular membranes, Her14 cells were stimulated for 20 min with H2O2. Next, the
cells were homogenised in homogenisation buffer containing EGTA to create calcium free
conditions. The homogenate of control and H2O2-stimulated cells were subjected to
ultracentrifugation to obtain a cytosolic and a membrane fraction. cPLA2 protein was
analysed on western blot and despite the calcium free conditions, a significant amount of
cPLA2 was translocated to the membrane fraction upon H2O2 stimulation as compared to
control cells (fig. 5A). This is interestingly since no translocation of cPLA2 occurred in
calcium ionophore-stimulated Her14 cells under calcium free conditions (Bunt et al., 1997).
No significant difference was detected in the amount of cPLA2 present in the cytosolic
fractions between control and stimulated cells (fig. 5A). This indicates a tight binding of
cPLA2 to the membranes under calcium free conditions.
Next, cPLA2 activity was measured in the homogenates of control and H2O2-
stimulated cells to ensure that cPLA2 was activated (fig. 5B, left columns). No difference in
cPLA2 activity was measured in the cytosolic fractions (fig. 5B, middle columns), while a
significant increase in cPLA2 activity in the membrane fraction of H2O2 treated versus
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Figure 4. Effect of phosphatase treatment on cPLA2 activity in EGF- and H2O2-stimulated
Her14 cells. Quiescent Her14 cells were either left untreated or stimulated with EGF (5 min) or H2O2
(20 min). The obtained cell lysates were either left untreated or incubated with alkaline phosphatase
whereafter cPLA2 activity was measured as described in Materials and Methods.
control cells was measured (fig. 5B, right columns). Thus, these data suggest that H2O2
might peroxidise membrane phospholipids in vivo thereby enhancing cPLA2 activity.
Discussion
In this study, we examined whether cPLA2 is activated by H2O2 and determined the
pathways by which cPLA2 is activated. First we showed that cPLA2 is similarly activated
by the oxidants H2O2 and cumene hydroperoxide in a dose dependent manner in Her14
fibroblasts, being maximal at around 2 and 1 mM, respectively. cPLA2 was rapidly and
transiently activated in response to H2O2 and returned to basal level after 60 min. 
An important step in cPLA2 activity regulation is phosphorylation of cPLA2,
thereby increasing its intrinsic activity by 2-3 fold (Nemenoff et al., 1993; Kramer et al.,
1993). In many cells, activation of p42/44MAPK has been shown to mediate cPLA2
phosphorylation and activation (for reviews Leslie, 1997; Murakami et al., 1997). In
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Figure 5. H2O2-induced cPLA2 translocation (A) and activity (B) in Her14 cells. Quiescent cells
were stimulated with H2O2 for 20 min, whereafter the cells were harvested under calcium free
conditions. Subsequently, part of the homogenate was centrifuged at 200,000xg to obtain the
particulate and cytosolic fraction. Ten µg of protein was used for electrophoresis and cPLA2 protein
was analysed on western blot (A). cPLA2 activity was measured in homogenate, cytosolic and
particulate fractions of stimulated and control cells (B).
addition, p38MAPK has been demonstrated (Kramer, et al., 1996; Börsch-Haubold, et al.,
1998) and JNK has been implicated in cPLA2 activation (van Putten, et al., 2001). H2O2-
induced cPLA2 activity in Her14 cells is partially mediated by p42/44
MAPK, because both
PD098059 and U0126 were unable to inhibit cPLA2 activity completely. p42/44
MAPK was
activated via the Raf-MEK pathway while, in addition, a secondary response in p42/44MAPK
phosphorylation occurred after 30 min, which was Raf-MEK independent. Furthermore,
treatment of quiescent cells with PD098059 completely inhibited p42/44MAPK
phosphorylation, that corresponded with a decrease in cPLA2 activity, showing that
p42/44MAPK and cPLA2 were activated via Raf-MEK, as has been shown previously (van
Rossum, et al., 2001). The remaining cPLA2 activity that was not inhibited by either
PD098059 or U0126 could be mediated by one of the other MAPK family members.
However, alkaline phosphatase treatment of H2O2-stimulated cells did not reduce cPLA2
activity to basal levels, in contrast to EGF-stimulated cells, which has been reported
previously (Schalkwijk, et al., 1995). Thus the remaining cPLA2 activity is not mediated by
phosphorylation through p38MAPK, JNK or any other kinase.
It has been demonstrated that ROS are able to peroxidise lipids from
biomembranes in vivo (Drummen, et al., 1999). This can lead to changes in ion permeability,
surface charge (Kühn et al., 1983), cell signalling (Keller & Mattson, 1998; Uchida et al.,
1999) and altered membrane fluidity (Imai et al., 2000) of the cell. Changes in membrane
fluidity due to oxidised lipids have been shown to increase PLA2 activity (Salgo et al., 1993;
van den Berg et al., 1993), that was suggested to be due to a change in molecular surface
area and structural composition of peroxidised versus unperoxidised membranes.
Alternatively, H2O2 peroxidised lipids may create a polar nature, which facilitates the
displacement of the released arachidonic acid from the membrane, thereby prolonging the
catalytic activity of cPLA2, which usually is subject to product inhibition (Reynolds et al.,
1993;  Bayburt & Gelb, 1997; Burke et al., 1999). H2O2 is able to raise the intracellular
calcium concentration (Golconda et al., 1993), which might result in cPLA2 translocation
and binding to membranes, whereupon cPLA2 is maximal activated (Abdullah, et al., 1995;
Schalkwijk, et al., 1996). Additionally, lipid peroxidation is known to increase the negative
surface charge of membranes allowing increased calcium binding (Vladimirov et al., 1980).
Furthermore, peroxidised lipids also decrease the calcium requirement for cPLA2 activity
(Rashba-Step, et al., 1997), suggesting that cPLA2 translocation and binding to membranes
is facilitated. Indeed, the H2O2-induced cPLA2 activity reside in the membrane fraction,
even under calcium free conditions, which did not occur in calcium-ionophore-stimulated
Her14 cells (Bunt, et al., 1997). Rahsba-Step et al. (1997) suggested that the effects of
membrane peroxidation and phosphorylation on cPLA2 activity are additive. We suggest
that the increased activity of cPLA2 due to membrane peroxidation might merely be due to
an increase in substrate availability for cPLA2.
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Abstract
Cytosolic phospholipase A2 (cPLA2) is of special interest because it selectively
releases arachidonic acid from membrane phospholipids. Arachidonic acid has been
implicated to play an important role in various cellular responses. Recently
arachidonic acid release and prostaglandin synthesis have been shown to be cell cycle
dependent and therefore the activity of cPLA2 during the ongoing cell cycle was
investigated, using the mitotic shake off method for cell synchronisation. cPLA2
activity was high in mitotic cells and decreased rapidly in the early G1 phase. A strong
increase in activity was measured following the G1/S transition in both neuroblastoma
and Chinese hamster ovary cells. The changes in activity were not due to a difference
in cPLA2 expression but due to phosphorylation of cPLA2. Phosphorylation of cPLA2
occurs through MAPK since the use of a specific MAPK kinase inhibitor and serum
depletion of synchronised cells inhibited cPLA2 activity.
Introduction
The 85 kDa cytosolic phospholipase A2 (cPLA2) preferentially catalyses the hydrolysis of
phospholipids at the sn-2 position generating arachidonic acid. The released arachidonic
acid can be oxygenated either by cyclooxygenase to form prostaglandins and thromboxanes
or by lipoxygenase to form leukotrienes. Arachidonic acid and/or its metabolites have been
implicated to play an important role in various cellular responses such as cell migration,
mitogenic signalling (Piomelli, 1993; Korystov Yu et al., 1998), inflammation (Heller et al.,
1998) and cytotoxicity (Cifone et al., 1993; Grazia Cifone et al., 1997). cPLA2 activity is
regulated by phosphorylation in addition to calcium-dependent binding to the membrane
substrate (Clark et al., 1995). Phosphorylation of cPLA2 increases its intrinsic enzyme
activity by 2 to 3-fold (Nemenoff et al., 1993; Kramer et al., 1993) and was shown to be
mediated by p42/44MAPK (ERK1/2 or MAPK) on Ser505 upon cell activation (Schalkwijk et
al., 1995; de Carvalho et al., 1996). Furthermore, for full activation of cPLA2, the enzyme
needs first to be phosphorylated followed by translocation to membranes by calcium
(Schalkwijk et al., 1996; Abdullah et al., 1995). 
The cell cycle can be divided into four phases: the first gap phase (G1), DNA
synthesis (S), the second gap phase (G2) and mitosis (M). At a point in G1, the restriction
point (R), the cell is committed to progress into S phase independently of growth factors
(Pardee, 1974). ERK1/2 activation plays an important role in cell cycle progression in both
G0 stimulated cells but also during the ongoing cell cycle (Pagès et al., 1993; Le Gall et al.,
1998). Both growth factor signalling and signal transduction routes resulting from cell
attachment can activate MAPK (Seger & Krebs; 1995; Giancotti, 1997; Hulleman et al.,
1999a).
Recently MAPK expression and phosphorylation was reported during G1 phase of
the cell cycle in Chinese hamster ovary (CHO) cells (Hulleman et al., 1999b). In addition,
phosphorylated ERK1/2 translocated to the nucleus during mid/late G1 of the cell cycle. As
pointed out earlier, MAPK is able to phosphorylate cPLA2, which upon translocation to
membranes releases arachidonic acid. It has been reported that arachidonic acid was
released from interphase cells in response to hormones, and that this release becomes
strongly inhibited in mitotic cells (Berlin & Preston, 1995). The use of phospholipase A2
inhibitors in tumour cells resulted in a suppressed proliferation of the cells by inducing
apoptosis (Korystov Yu et al., 1998). Therefore we investigated whether cPLA2 activity is
cell cycle dependent since ERK1/2 activity alters and arachidonic acid release differs during
the cell cycle. 
We report that cPLA2 activity is high in mitosis, decreases afterwards and is
increased again in G1 and following the G1/S transition. At these periods, cPLA2 activity is
due to increased phosphorylation rather than by increased cPLA2 protein expression, since
phosphatase treatment of cPLA2 reduced its activity. Moreover, preventing phosphorylation
of MAPK either by inhibiting the upstream activator MEK, or by serum depletion of
synchronised cells resulted in a decrease in cPLA2 activity. The knowledge of cPLA2
activity during the ongoing cell cycle is of great importance since cPLA2 generates
arachidonic acid, which has in some tumour cells proliferative (Adachi et al., 1996; Tang et
al., 1997) and in other tumour cells apoptotic effects (Korystov Yu et al., 1998; Chan et al.,
1998). Also the cyclooxygenase and lipoxygenase enzymes which can convert arachidonic
acid into bioactive lipids have been implicated to play a role in tumorigenesis (Ikawa et al.,
1999; Sawaoka et al., 1999).
Materials and Methods
Cell culture.
Neuroblastoma (N2A) or Chinese hamster ovary (CHO) cells were grown in
Dulbeccos modified Eagles medium (DMEM, Gibco BRL, Scotland) supplemented with
25 mM HEPES and 7.5% foetal bovine serum (FBS, Gibco BRL, Scotland). Cells were
maintained at 37°C in a humidified atmosphere.
Mitotic shake off.
One day prior to shake off, cells were cultured at 5x106 cells per 175 cm2 flask.
Each hour flasks were shaken for 1 min at 37°C to obtain mitotic cells, which were replated
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on tissue culture dishes as described previously (Boonstra et al., 1981). The cells were
harvested at different hours after mitosis, by removing the medium and washing the cells
twice with ice-cold phosphate buffered saline (PBS). Thereafter, the cells were scraped in
homogenisation buffer (50 mM Hepes/NaOH pH 7.4, 0.25 M sucrose, 50 mM NaF, 250 µM
Na3VO4, 1 mM EGTA, 10 µM leupeptin, 1 µM pepstatin and 1 mM PMSF). Cells were
homogenised by 15 strokes through a 26G needle and sonicated for 3 times 10 seconds.
Mitotic cells were centrifuged at 600xg for 7 min whereafter the cells were washed twice
and either harvested, or replated on tissue culture dishes in serum-free medium. Then the
cells were harvested at the indicated times. In other experiments mitotic cells were replated
on tissue culture dishes and at different hours after mitosis incubated for 10 min with 50 µM
of the MEK inhibitor U0126 (Promega, Madison, USA), whereafter the cells were harvested
as described above.
Western blot analysis. 
Proteins of 1x105 cells per time point were separated on 10% SDS-PAGE and
transferred to polyvinylidene difluoride membrane by semi-dry blotting using a BioRad
trans-blot SD. The membrane was blocked for 1 h at RT with 2% milk powder in PBST
(PBS containing 0.1% (v/v) Tween-20) following primary antibody incubations for 1 h in
0.2% milk powder in PBST. Cyclin A (Calbiochem, Cambridge, UK) and p42MAPK (Upstate
Biotechnology, Lake Placid, NY) were detected with a monoclonal antibody at a dilution of
2.5 µg/ml and 0.5µg/ml, respectively. Phosphorylated ERK1/2 was detected with a
phospho-p42/44 MAPK rabbit polyclonal antibody (dilution of 1:8000) from New England
Biolabs Incorporated (Beverly, MA). cPLA2 was detected with a rabbit polyclonal antibody
(0.2 µg/ml) obtained from Santa Cruz Biotechnology (Heidelberg, Germany). Subsequently,
the membrane was washed and primary antibodies were detected with rabbit anti-mouse and
donkey anti-rabbit IgG conjugated to horseradish peroxidase and the bands were visualised
with enhanced chemiluminescence (NENTM Life science products, Boston).
cPLA2 activity assay.
cPLA2 activity was measured by the release of radiolabeled arachidonic acid from
the sn-2 position of 1-stearoyl-2-[1-14C]arachidonoyl-glycero-3-phosphocholine (Amersham,
Buckinghamshire, England) as described previously (Schalkwijk et al., 1996). Briefly,
aliquots of the radiolabeled phosphatidylcholine  was dried under N2 together with
dipalmitoylglycerol (Sigma, Steinheim, Germany) and then dispersed in water by
sonification for 4 times 15 sec under nitrogen to give final concentrations of 4 µM and 2
µM, respectively, in the assay. The assay incubation mixture contained 0.2 M Tris pH 8.5, 1
mM CaCl2, 5 mM DTT and the homogenate of 2x10
5 cells in a total volume of 200 µl. After
incubation for 7-10 min at 37°C the released radiolabeled arachidonic acid was extracted by
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a modified Dole extraction procedure (van den Bosch et al., 1974) and the radioactivity was
determined in a scintillation counter (Tri-Carb 15000, Packard, Meriden, USA). Measuring
the activity of non-phosphorylated cPLA2 was performed as described previously
(Schalkwijk et al., 1995) by addition of 10 units alkaline phosphatase (Roche diagnostics,
Mannheim, Germany) to an assay mixture containing the homogenate of 2x105 cells, 1 mM
MgCl2, 0.25 M Tris pH 8.5, 1.25 mM CaCl2 and 6.25 mM DTT in a final volume of 160 µl.
After a 20 min incubation at 37°C, 40 µl substrate was added and the cPLA2 activity assay
was performed as described above. Under these assay conditions always less than 5% of the
substrate was hydrolysed.
Results
cPLA2 activity during the cell cycle.
It has been previously reported that in HeLa cells arachidonic acid release was cell
cycle independent (Lahoua et al., 1989) but in fibroblasts arachidonic acid was released
from interphase cells which could be the result of activated phospholipases A2 (Berlin &
Preston, 1995). Since cPLA2 is known to selectively liberating arachidonic acid, we
examined whether cPLA2 activity changes during the G1 and/or S phase of the ongoing cell
cycle in neuroblastoma cells (N2A), by using the mitotic shake off method for cell
synchronisation (Boonstra et al., 1981). Detection of the S phase cyclin A on western blot
or 3H-thymidine incorporation into the DNA of the cells as described by Hulleman et al.,
(1999a) was used to assess the G1/S-phase transition of N2A cells. Synchronised N2A cells
were harvested at different hours after mitosis and cPLA2 activity of an identical amount of
cells was determined using an in vitro assay as described in Materials and Methods in which
only the activity of cPLA2 was measured (Spaargaren et al., 1992; Schalkwijk et al., 1992;
Atsumi et al., 1998). Figure 1A shows in N2A cells a decrease in cPLA2 activity during the
first hours after mitosis, followed by a small peak in G1 and a strong increase starting at the
G1/S phase transition. In Chinese hamster ovary (CHO) cells the activity of cPLA2
remained constant during the early G1 (fig. 1B). Thereafter, the activity slightly decreased
to increase transiently, which at the G1/S phase transition significantly increased again.
Except for the decrease in activity after mitosis a similar cPLA2 activity pattern was
determined in CHO cells as observed in synchronised N2A cells, implying that this pattern
is not cell type specific. However, there are slight differences at the timing of the peaks
between experiments, which is mostly due to variations in the length of the G1 phase
(Zetterberg & Larsson, 1991). 
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To investigate whether these changes in cPLA2 activity are the result of differences
in expression level, the total amount of cPLA2 protein was analysed on western blot (fig.
2A), showing small differences in cPLA2 protein expression during the cell cycle. In order
to establish the significance of the cell cycle related changes in cPLA2 expression the bands
of four different experiments were quantified and the average percentage of expression,
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Figure 1. Activity of cPLA2 in (A) N2A and (B) CHO cells. Cells were synchronised by mitotic
shake off and were harvested at different hours after mitosis. cPLA2 activity was measured of 2x10
5
cells using an in vitro assay as described in Materials and Methods. G1/S phase transition was detected
on western blot by cyclin A expression. Similar data were obtained in respectively 8 (A) and 2 (B)
separate experiments, each performed in duplicate.
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relative to mitotic cells, was calculated. As shown in figure 2D the cPLA2 expression
gradually increases about two-fold during the cell cycle, with a slightly stronger increase
between 4 and 6 hours after mitosis. cPLA2 protein expression is nearly constant until 3
hours after mitosis while cPLA2 activity is decreased by approximately 50%. A rise in
protein expression was observed between 4-6 hours but does not result in grossly different
cPLA2 activities. By contrast, the cPLA2 expression does not change in the time period from
6 to 9 hours, while the cPLA2 activity increases over 2-fold between 6 to 8 hours and
decreases again from 8-9 hours (fig. 1).  These data suggest that cPLA2 activity during the
cell cycle, in particular the increase in early S-phase, is regulated by other factors, such as
phosphorylation. 
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Figure 2. Expression of (A) cPLA2; (B) p42
MAPK; (C) phosphorylated p42/44MAPK and (D)
quantification of cPLA2 protein expression during the cell cycle. Synchronised N2A cells were
harvested at the indicated hours after mitosis whereafter, 1x105 cells were used for electrophoresis and
the following proteins were analysed on western blot. A: Expression of cPLA2. B: Expression of
p42MAPK. C: Phosphorylation of p42/44MAPK. D: cPLA2 protein expressions of four separate
experiments were quantified and the average percentage of cPLA2 protein and S.E.M relative to
mitotic cells was calculated.
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In stimulated cells, the phosphorylation of cPLA2 by ERK1/2 has been shown to
play an important role in the release of arachidonic acid (Clark et al., 1995; Murakami et al.,
1997) and is required for maximal activation of cPLA2 (Lin et al., 1993; Kramer et al., 1996;
Qiu et al., 1998). So far, nothing is known about the involvement of MAPK in the activation
of cPLA2 during the ongoing cell cycle. Recently it has been demonstrated in CHO cells that
MAPK is continuously expressed during the cell cycle and that only a minor part is
phosphorylated in the G1 and S phase (Hulleman et al., 1999b). The expression of MAPK
(fig. 2B) was examined to serve as an internal control. In addition, MAPK phosphorylation
was analysed on western blot (fig. 2C), using an antibody directed against phosphorylated
p42/44MAPK. MAPK protein expression remained fairly constant during the cell cycle while
ERK1/2 is phosphorylated during the G1 and even more so in S phase but not in mitosis.
From these results no direct relationship between ERK1/2 phosphorylation and cPLA2
activity could be drawn. The gradual changes in MAPK phosphorylation do not account for
the more sudden variations in cPLA2 activity.
Regulation of cytosolic phospholipase A2 by phosphorylation during the ongoing cell cycle.
cPLA2 activity is regulated by calcium since cPLA2 binds to membranes in a
calcium dependent manner. Another important factor that enhances and regulates cPLA2
activity is phosphorylation of the enzyme. Phosphorylation of cPLA2 can occur through
different MAPKs, like p38MAPK in thrombin-stimulated platelets (Kramer et al., 1996) and
ERK1/2 (Nemenoff et al., 1993; Qiu et al., 1998), of which the latter one has been found to
phosphorylate and activate cPLA2 in many cell models, and which has also been shown to
be essential for progression through the cell cycle (Pagès et al., 1993; Le Gall et al., 1998).
In order to establish the role of ERK1/2 in cPLA2 activation, ERK1/2 activation was
prevented using the MAPK kinase (MEK) inhibitor U0126. U0126 inhibits MEK directly
by inhibiting the catalytic activity of the enzyme and thus the activation of ERK1/2 (Favata
et al., 1998). Synchronised N2A cells were either left untreated or were, at different hours
after mitosis, treated for 10 min with U0126 whereafter the cells were harvested (fig. 3). In
this way it is unlikely that the MEK inhibitor affects cell cycle progression. The activity of
cPLA2 in control cells showed again a decrease after mitosis, followed by a peak in G1 and
a peak after the G1/S transition (fig. 3A). In cells treated with the MEK inhibitor, cPLA2
activity is lower as compared to control cells, however the pattern is similar. Furthermore,
in mitosis, at the end of G1 and following the G1/S transition a reduction of approximately
50% in cPLA2 activity was observed between control and U0126 treated cells. In agonist-
stimulated cells an increase of 2-3 fold in cPLA2 activity by MAPK was measured (Lin et
al., 1993) which might well be the activity that is reduced upon U0126 treatment. The
effects of calcium that might influence cPLA2 activity during the cell cycle was eliminated
by determining the activity in vitro under constant calcium concentrations and thus the
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activities measured are not affected by calcium fluctuations. This suggests that at these
periods cPLA2 is activated by MAPK. In addition, western blot analysis displays
phosphorylated MAPK in control cells while this appears to be virtually completely
inhibited in U0126 treated cells (fig. 3B) showing that with a 10 min treatment of this
inhibitor MAPK was not phosphorylated anymore. Despite this nearly complete inhibition
of MAPK phosphorylation the cPLA2 activity is not completely inhibited. This can be due
to the residual activity of either the non-phosphorylated form of cPLA2 (Lin et al., 1993) or
of some residual active and phosphorylated enzyme that was present at the moment of
addition of U0126 and has not yet been completely de-phosphorylated during the 10 min
treatment with the inhibitor. 
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Figure 3. cPLA2 activity (A) and MAPK phosphorylation (B) in the absence (J) or presence(C)
of the MEK inhibitor U0126. N2A cells synchronised by mitotic shake off were replated on tissue
culture dishes. Cells were harvested at the indicated time points or were then treated for 10 min with
the specific MEK inhibitor, U0126, whereafter these cells were harvested. cPLA2 activity was
measured as described in Materials and Methods (A) and phosphorylated MAPK was analysed on
western blot (B).
The results from figure 3 suggest that during the cell cycle cPLA2 is at least in part
phosphorylated by MAPK, thereby increasing its activity at distinct periods. To evaluate
whether the increase in cPLA2 activity at these periods is indeed due to phosphorylation of
the enzyme, the effect of phosphatase treatment on cPLA2 activity was investigated. cPLA2
activity of synchronous cells at different hours after mitosis was measured resulting in the
characteristic activity pattern during the ongoing cell cycle. Next, mitotic cells, cells from
early and late G1 and of S phase were treated with alkaline phosphatase whereafter cPLA2
activity was measured. Figure 4 shows in mitotic cells as well as in late G1 and S phase cells
a remarkable reduction in cPLA2 activity of approximately 64, 49 and 45% respectively as
compared to control, while only a marginal decrease of 21% in activity was measured in
early G1 cells. This is also the period in which cPLA2 has a reduced activity during the cell
cycle. These results are in agreement with the reduced activities measured in synchronous
cells treated with the MEK inhibitor U0126 (fig. 3), indicating that indeed cPLA2 activity
during the cell cycle is enhanced through phosphorylation by MAPK. 
In order to further establish the involvement of MAPK in cPLA2 activation a more
in vivo approach was used. MAPK in stimulated cells can be activated either by growth
factors or via cell attachment (Seger & Krebs, 1995; Lin et al., 1997; Giancotti, 1997), but
has recently been shown to be growth factor dependent during the ongoing cell cycle
(Hulleman et al., 1999a). Therefore, mitotic cells were replated either on tissue culture
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Figure 4. Effect of phosphatase treatment on cPLA2 activity. cPLA2 activity of synchronised N2A
cells at different hours after mitosis was measured and mitotic cells, cells from early and late G1, and
of S phase were treated with alkaline phosphatase whereafter the activity was measured as described
in Materials and Methods. 
dishes in the presence or absence of serum for the indicated hours (fig. 5). In this way
MAPK that is activated through growth factors is eliminated (Hulleman et al., 1999a).
Western blot analysis confirmed that cells replated in serum free medium did not exhibit
phosphorylated ERK1/2 in contrast to control cells (fig. 5A).  In addition, cPLA2 activity of
serum-deprived cells rapidly decreased after mitosis and remained at a low level for at least
3 hours as compared to control cells (fig. 5B). Measurements of longer time points were not
performed since serum-deprived cells will stop cell cycle progression. All together, these
results also demonstrate that cPLA2 activity is increased through phosphorylation by MAPK. 
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Figure 5. Effect of serum depriviation on (A) MAPK phosphorylation and (B) cPLA2 activity.
Mitotic N2A cells obtained with the mitotic shake off method were either directly replated on a tissue
culture dish in the presence of serum (monolayer + serum; solid line) or in the absence of serum
(monolayer  serum; dashed line). After harvesting at the indicated time points, MAPK
phosphorylation was analysed on western blot and cPLA2 activity was measured in vitro as described
in Materials and Methods.
Discussion
Arachidonic acid is known to be able to fulfil different cellular responses and is
selectively released by cPLA2. In order to establish the possible role of cPLA2 in the cell
cycle, cPLA2 activity was measured during the cell cycle of N2A and CHO cells
synchronised by mitotic shake off. cPLA2 activity during the phases of the cell cycle was
measured by an in vitro assay showing that cPLA2 is highly active in mitosis which is
decreased rapidly afterwards. However, Berlin and Preston (1995) found no arachidonic
acid release in metaphase-arrested HeLa cells stimulated with calcium releasing agents. This
was surprisingly, since the activity measured in vitro and protein expression of mitotic and
interphase cells were comparable and even though mitotic cPLA2 was constitutively
phosphorylated in unstimulated cells (Berlin & Preston, 1995). However, these authors used
an anti-mitotic drug to synchronise the cells, that may have effects on cell cycle progression
(Schmid-Alliana et al., 1998). Moreover, arachidonic acid release was not measured during
the ongoing cell cycle. 
We measured an elevated transient activity of cPLA2 during the G1 phase that is
followed by a strong increase in the S phase. This activation pattern of cPLA2 has not only
been observed in neuroblastoma cells but also in CHO cells, demonstrating that this pattern
is not cell type specific and can also be found in other cell types. No correlation between
cPLA2 activity during the ongoing cell cycle with variations in cPLA2 expression levels was
found suggesting that the activity is regulated by other factors. In addition, in cryosections
of Her 14 fibroblasts it was shown that cPLA2 exists as monomers but is, next to this,
predominantly present in clusters (Bunt et al., 1997). These clusters then represent the
inactive form of cPLA2 of which small amounts of active monomers are recruited which are
localised to the membrane (Bunt et al., 2000). Furthermore, although the expression levels
vary, nothing is known about the percentage of active monomers that account for the cPLA2
activity pattern during the cell cycle. 
cPLA2 activity is predominantly regulated by calcium and phosphorylation, of
which the latter one has to precede the calcium-dependent translocation for its full activation
(Schalkwijk et al., 1996). In this study we investigated the regulation of cPLA2 activity by
phosphorylation during the ongoing cell cycle. Western blot analysis showed no direct
relationship between phosphorylated MAPK and cPLA2 activity. Therefore, MAPK
activation was prevented by inhibiting MEK activity with a specific inhibitor showing that
there is indeed a relation between ERK1/2 phosphorylation and cPLA2 activity during the
ongoing cell cycle. A clear inhibition of cPLA2 activity using U0126 was only observed in
mitosis, late G1 and S phase where cPLA2 is found to be highly active in control cells. In
addition, treatment of cPLA2 at these periods with alkaline phosphatase resulted also in a
reduction of approximately 50% in cPLA2 activity as was also observed when MAPK
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phosphorylation was inhibited. Almost no reduction in activity was measured in periods
where cPLA2 activity during the cell cycle was low suggesting that this represents the basal
activity. It seems as if the changes in cPLA2 activity during the ongoing cell cycle in both
N2A and CHO cells are modest. It has been published that cPLA2 could only be activated
about 2-3 times above basal level upon phosphorylation (Qiu et al., 1993; Kramer et al.,
1993; Schalkwijk et al., 1995) which resembles the decrease in activity upon phosphatase
treatment or MAPK inhibition in our cells.  
The relation between phosphorylated MAPK and cPLA2 activity was further
established by preventing the existence of phosphorylated MAPK in cells by growing
mitotic cells in the absence of serum (Hulleman et al., 1999a). In these cells cPLA2 activity
was markedly decreased as compared to control cells in which MAPK was phosphorylated.
All together, these results indicate that MAPK phosphorylates cPLA2 thereby activating the
enzyme in a growth factor dependent way in the G1 and S phase of the ongoing cell cycle.
Our findings are of particular interest in view of cell cycle progression since both
MAPK and especially cPLA2 are involved in tumorigenesis (Adachi et al., 1996; Korystov
Yu et al., 1998). Firstly, Lahoua et al. (1989) showed that biosynthesis of PGE2 and PGF2α,
metabolites of arachidonic acid,  was increased in S phase, i.e. in the same phase in which
we measured a high cPLA2 activity. Secondly, in hepatocytes quinacrine, a commonly used
phospholipase A2 inhibitor, prevented hepatocyte growth factor induced arachidonic acid
release and 3H-thymidine incorporation (Adachi et al., 1996). An effect that was also found
in tumour cells treated with phospholipase A2 and lipoxygenase inhibitors (Korystov Yu et
al., 1998). 
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Abstract
Arachidonic acid has been implicated in regulating cellular proliferation, and
is preferentially released by the 85 kDa cytosolic phospholipase A2 (cPLA2). Recently,
we demonstrated that cPLA2 is activated in distinct periods during the ongoing cell
cycle of neuroblastoma cells. The purpose of the present study was to establish the role
of these cPLA2 activity peaks in cell cycle progression. Inhibition of cPLA2 activity
with arachidonyl trifluoromethylketone (ATK) in early G1 phase resulted in a marked
reduction in DNA synthesis, whereas inhibitors for sPLA2 and iPLA2 had no
remarkable effect. A 24h incubation of neuroblastoma cells with ATK, in which cPLA2
activity was still inhibited, revealed no significant difference in cell number as
compared to untreated cells. This suggests redundancy of the different PLA2 enzymes.
Lipoxygenase inhibition in early G1 resulted in G1 phase arrest, whereas inhibitors for
cyclooxygenase had no effect. Furthermore, cells stopped progressing through S phase
when lipoxygenase was inhibited in early S phase, demonstrating the requirement of
lipoxygenase products for S phase progression. 
Introduction
The factors that determine whether cells continue to proliferate, arrest growth or
differentiate, are activated by signals from the extracellular environment and operate
predominantly during the G1 phase of the cell cycle. Progression through the cell cycle is
regulated by cyclin-dependent kinases (Cdks) that are activated upon binding with their
cyclins, and by multiple phosphorylation and dephosphorylation steps (Nigg, 1995; Dirks &
Rutka, 1997; Reed, 1997). The activity of Cdks is negatively regulated by Cdk inhibitory
proteins that constists of two families of which the INK4 family specifically inhibits cyclin
D/Cdk4,6 complexes, while the Kip/Cip family inhibits most cyclin/Cdk2,4 and 6
complexes (Sherr & Roberts, 1995; Hulleman & Boonstra, 2001). The first cyclin/Cdk
complex in the G1 phase is activated by growth factors and consists of cyclin D and Cdk4
or 6 (Sherr, 1995), resulting in retinoblastoma phosphorylation and the subsequent
activation of cyclin E/Cdk2. Furthermore, activated p42/44MAPK was shown to induce cyclin
D expression and down-regulation of p27Kip (Aktas et al., 1997; Cheng et al., 1998). In
addition, a sustained activation of p42/44MAPK is required to pass the restriction point,
whereas inhibition of p42/44MAPK blocks DNA synthesis and proliferation (Pagès et al.,
1993; Hulleman et al., 1999; Roovers et al., 1999). Also, p42/44MAPK overexpression was
observed in human breast cancer cells (Sivaraman et al., 1997), showing the importance of
p42/44MAPK activity in cell proliferation. 
Recently, it was demonstrated that cytosolic phospholipase A2 (cPLA2) activity was
cell cycle dependent and furthermore, cPLA2 phosphorylation in these periods was mediated
by p42/44MAPK (van Rossum et al., 2001). cPLA2 releases preferentially arachidonic acid
from membrane phospholipids. The released arachidonic acid can be metabolised by
cyctochrome p450s, cyclooxygenases, or by lipoxygenases to produce eicosanoids.
Arachidonic acid and/or its metabolites appear to have an important role in growth-
dependent signalling pathways and are involved in mitogenic signalling, cell migration and
cytotoxicity (Piomelli, 1993; Sa & Fox, 1994; Grazia Cifone et al., 1997). Furthermore,
most tumour cells produce elevated levels of eicosanoids that result in an induced growth
and invasiveness of the tumours (Reich & Martin, 1996). Accordingly, in oncogenic ras
transformed lung cancer cells, cPLA2 expression was found to be constitutively high
(Heasley et al., 1997). 
To gain more insight in the mode of action of cPLA2 in cell proliferation we studied
the role of cPLA2 activity in cell cycle progression. We present for the first time that cPLA2
activity in G1 phase was required for progression into S phase. Neither iPLA2 nor sPLA2
are involved in progression to S phase. cPLA2 inhibition for 24h resulted in a comparable
cell number of ATK treated versus untreated cells, suggesting redundancy of the different
PLA2 enzymes. By using inhibitors we assessed the involvement of lipoxygenase, but not
cyclooxygenase in cell cycle progression into S phase. Moreover, lipoxygenase inhibition in
early G1 resulted in G1 phase arrest. DNA synthesis and S phase progression is blocked
when lipoxygenase is inhibited in early S phase, demonstrating that lipoxygenase
metabolites are required for S phase progression.
Materials and Methods
Materials.
Tissue culture nutrients, Dulbeccos modified Eagles medium supplemented with
25 mM HEPES (DMEM-HEPES) and foetal bovine serum (FBS) were purchased from
Gibco BRL (Scotland). Methyl-[3H]-thymidine (2 mCi/mmol) was obtained from
Amersham (Arlington Heights, IL). Arachidonyl trifluoromethylketone (ATK), bromoenol
lactone (BEL), 5(S)-HpETE and 12(S)-HpETE were acquired from Cayman chemical (Ann
Arbor, USA). Manoalide was from Biomol (Playmouth meeting, USA) and, NS-398 and
caffeic acid were obtained from Calbiochem (La Jolla, USA). 4-Bromophenacyl bromide
(4-BPB), indomethacin, nordihydroguaiaretic acid (NDGA) and arachidonic acid were
purchased from Sigma-Aldrich chemie (Steinheim, Germany). All other chemicals were
either from Sigma or Merck (Darmstadt, Germany).
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Cell culture and cell synchronisation. 
Neuroblastoma (N2A) cells were grown in DMEM-HEPES supplemented with
7.5% foetal bovine serum. Cells were maintained at 37°C in a humidified atmosphere. One
day prior to shake off, cells were cultured at 5x106 cells per 175 cm2 flask. Each hour flasks,
containing asynchronous cells, were shaken for 1 min at 37°C to obtain mitotic cells as
described previously (Boonstra et al., 1981). 
[3H]-thymidine incorporation.
Mitotic cells were plated in 24-wells plates at a density of 3x104 cells per well in
DMEM-HEPES containing 7.5 % FBS and 1 µCi [3H]-thymidine/well. At the indicated
times, the cells were washed twice with phosphate-buffered saline (PBS) whereafter, the
cells were dissolved in 0.1 M NaOH and the incorporated [3H]-thymidine was counted in a
scintillation counter (LS 6000 SE, Beckman Instruments, Fullerton, CA). In other
experiments, as indicated, [3H]-thymidine incorporation was started 3 hours ahead of the
actual experiment as a control. Then at the indicated times after mitosis half of the cells were
incubated with ATK (10 µM) to inhibit cPLA2 or with NDGA (10 µM) to inhibit
lipoxygenase. After 30 min, [3H]-thymidine was added to both control and ATK or NDGA
treated cells. Fifteen min later the cells were washed twice with PBS, then washed with 10%
trichloroacetic acid, washed again twice with PBS, whereafter the cells were dissolved in
0.1 M NaOH and [3H]-thymidine incorporation was measured. 
Western blot analysis.
Mitotic cells were replated and at the indicated times after mitosis the medium was
removed and the cells were washed twice with ice-cold PBS. Subsequently, the cells were
scraped in homogenisation buffer (50 mM Hepes/NaOH pH 7.4, 0.25 M sucrose, 50 mM
NaF, 250 µM Na3VO4, 1 mM EGTA, 10 µM leupeptin, 1 µM pepstatin and 1 mM PMSF).
Cells were homogenised by 15 strokes through a 26G needle and sonicated for 3 times 10
seconds. Proteins of 1x105 cells per time point were separated on 10% SDS-PAGE and
transferred to polyvinylidene difluoride membrane by semi-dry blotting using a BioRad
trans-blot SD. The membrane was blocked for 1 h at RT with 2% milk powder in PBST
(PBS containing 0.1% (v/v) Tween-20) following primary antibody incubations overnight at
4°C in 0.2% milk powder in PBST. Cyclin A (Calbiochem, Cambridge, UK) was detected
with a monoclonal antibody at a concentration of 2.5 µg/ml. Subsequently, the membrane
was washed and primary antibodies were detected with rabbit anti-mouse IgG conjugated to
horseradish peroxidase and the bands were visualised with enhanced chemiluminescence
(NENTM Life science products, Boston).
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Results
cPLA2 activity in G1 phase is required for cell cycle progression.
We have previously demonstrated that cPLA2 activity is cell cycle dependent in
neuroblastoma (N2A) and Chinese hamster ovary (CHO) cells (van Rossum, et al., 2001),
being high in mitosis, thereafter decreasing in early G1. A small increase in activity was
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Figure 1. [3H]-Thymidine incorporation (A) and effect of ATK and 4-BPB on DNA synthesis (B)
in N2A cells, synchronised by mitotic shake off. (A) N2A cells were synchronised using the mitotic
shake off method. [3H]-Thymidine (1 µCi/well) was added to the mitotic cells and at the indicated
times after mitosis the incorporated radiolabel was quantified using a liquid scintillation counter. (B)
ATK (10 µM) and 4-BPB (10 µM) were added to synchronous cells at 1, 4 and 6h after mitosis and
left to incubate until 8h after mitosis, whereafter the incorporated [3H]-thymidine into the DNA was
measured. Data are means ± SD (n=3).
measured during mid/late G1, and a strong increase was measured following the G1/S
transition. In order to investigate whether cPLA2 activity is required for cell cycle
progression to S phase, the activity of cPLA2 was inhibited at different time points in G1
phase in N2A cells, which were synchronised by using the mitotic shake off method
(Boonstra, et al., 1981). Therefore, a non-specific PLA2 (4-bromophenacyl bromide; 4-
BPB) (Chang et al., 1987) and a potent reversible cPLA2 (arachidonyl trifluoromethyl
ketone; ATK) inhibitor (Street et al., 1993; Trimble et al., 1993) were used. Synchronous
cells were either left untreated, or were incubated with ATK (10 µM) or 4-BPB (10 µM)
from 1, 4 and 6h after mitosis. At 8h, at which most cells have entered the S phase (fig. 1A),
DNA synthesis was determined by measuring [3H]-thymidine incorporation of the cells as
described in Materials and Methods. As shown in figure 1B, [3H]-thymidine incorporation
was reduced approximately 60% as compared to control cells, if ATK is added 1h after
mitosis, while no reduction is measured when ATK is added at later time points. Apart from
the effect on DNA synthesis, inhibition of cPLA2 activity did not influence the total number
of cells, indicating that the inhibition of DNA synthesis was not due to cytotoxic effects of
ATK (data not shown). In addition, a similar pattern of [3H]-thymidine incorporation was
obtained in synchronous N2A cells treated with 4-BPB. These results indicate the
requirement of cPLA2 activity in G1 for cell cycle progression.
However, ATK has also been reported to be able to inhibit the Ca2+-independent
PLA2 (iPLA2) in macrophages, although at higher concentrations (Ackermann et al., 1995).
Therefore, it was investigated whether the reduction in [3H]-thymidine incorporation was
solely due to cPLA2 or due to other PLA2 isoforms as well. To discriminate between cPLA2
and iPLA2, bromoenol lactone (BEL) was used, which is a potent irreversible inhibitor of
iPLA2, but not of cPLA2 (Zupan et al., 1993; Ackermann, et al., 1995).  The involvement of
sPLA2 was investigated by the use of manoalide (Jacobson et al., 1990). BEL (2.5 µM) or
manoalide (0.1 µM) were added to synchronously growing cells at 2, 4 and 6h after mitosis,
or the cells were left untreated. The [3H]-thymidine incorporation measured at 8h was only
slightly reduced when BEL was added at 2 and 4h after mitosis as compared to control cells
(fig. 2). No effect was observed in cells incubated with BEL from 6h after mitosis.
Manoalide only marginally affected the [3H]-thymidine incorporation of the cells when
added at 2, but not at 4 or 6h as compared to control cells. This indicates that sPLA2 is not
and iPLA2 is at best only marginally involved in cell cycle progression to S phase.
It is, however, not clear whether cPLA2 inhibition results in cell cycle arrest or
whether it is just delayed. Therefore, cell count experiments were performed in which cells
were left untreated, or to which ATK was added at 0, 1 or 2h after mitosis. At 24h after
mitosis the total number of cells in ATK treated cells was similar to untreated cells (fig. 3)
and moreover was increased as compared to the total number of cells present at 8h, showing
that cells have completed their cell cycle. In addition, ATK was still functional, since cPLA2
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Figure 2. Effects of PLA2 inhibitors on cell cycle progression into S phase in N2A cells.
Synchronous N2A cells were left untreated, or incubated with ATK (10 µM), BEL (2.5 µM) and
manoalide (0.1 µM) from 2, 4 and 6h after mitosis. [3H]-Thymidine incorporation was measured at 8h
after mitosis. Data are the means ± SD (n=3).
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Figure 3. Long term cPLA2 inhibition does not result in cell cycle arrest. To synchronous N2A
cells, ATK (10 µM) was added at 0, 1 and 2h after mitosis and cells were left to incubate until 24h
after mitosis. Then, the total numbers of cells were counted. Data are means ± SD (n=2).
activity in synchronous cells treated for 8 or 24h with ATK was inhibited as compared to
untreated cells (data not shown). 
Collectively, these results show the requirement of cPLA2, but not iPLA2 or sPLA2,
in cell cycle progression, since 4-BPB did not reduce DNA synthesis any further than ATK,
whereas inhibitors for iPLA2 and sPLA2 displayed no significant effect. In addition, cPLA2
inhibition in early G1 results in a temporal inhibition of cell cycle progression. 
Lipoxygenase, but not cyclooxygenase are involved in cell cycle progression.
The arachidonic acid released by cPLA2, can be further metabolised by
cyclooxygenases or lipoxygenases into a large family of eicosanoids that have been
implicated amongst others, in mitogenic signalling, cytotoxicity and cancers (Dethlefsen et
al., 1994; Hsi & Eling, 1998; Shappell et al., 2001). To examine the role of cyclooxygenase
(COX) and lipoxygenase (LO) on cell cycle progression, we evaluated the effects of COX
and LO inhibitors on DNA synthesis. Indomethacin (Indo, 10 µM), a non-selective COX
inhibitor (Laneuville et al., 1994), and NS 398 (10 µM), a selective COX-2 inhibitor
(Copeland et al., 1994), were added at 2, 4 and 6h after mitosis and [3H]-thymidine
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Figure 4. Effects of cyclooxygenase and lipoxygenase inhibitors on cell cycle progression.
Synchronous N2A cells were left untreated, or incubated with the cyclooxygenase inhibitors Indo (10
µM) and NS 398 (10 µM), and the lipoxygenase inhibitors NDGA (10 µM) and CA (25 and 100 µM)
from 2, 4 and 6h after mitosis. The amount of [3H]-thymidine incorporated into the DNA was
measured at 8h after mitosis. Data are means ± SD (n=3).
incorporation was measured at 8h after mitosis. These inhibitors did not cause a significant
reduction in the [3H]-thymidine incorporation relative to control cells (fig. 4), demonstrating
that neither COX-1 nor COX-2 plays a role in G1/S phase progression. On the other hand,
a complete inhibition in [3H]-thymidine incorporation was measured at 8h when
lipoxygenase was inhibited from 2 or 4h after mitosis with 10 µM nordihydroguaiaretic acid
(NDGA), a potent inhibitor of lipoxygenases (Hope et al., 1983; Salari et al., 1984). Still an
inhibition of approximately 60% was observed upon addition of NDGA at 6h after mitosis.
These inhibitory effects of NDGA were not due to cytotoxic effects of NDGA, since the
total number of cells was similar to untreated cells (data not shown).  In contrast, 25 µM
caffeic acid (CA), which predominantly inhibits 5- and 12-LO but at higher IC50 values than
the common lipoxygenase inhibitor NDGA (Koshihara et al., 1984; Rao et al., 1993), was
not effective in inhibiting [3H]-thymidine incorporation. A significant inhibition of about 40
and 30%, respectively, was measured when 100 µM caffeic acid was added only at 2 and
4h. These results show that lipoxygenase, is involved in cell cycle progression to S phase
and that inhibition of lipoxygenase in early G1 may result in cell cycle arrest. We further
investigated whether lipoxygenase inhibition in G1 results in G1 phase arrest by
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Figure 5. Expression of cyclin A during the ongoing cell cycle. Cells were synchronised via mitotic
shake off, replated and harvested at the indicated times after mitosis as described in Materials and
Methods. Cell lysates of 1x105 cells were separated on SDS-PAGE whereafter, cyclin A was analysed
on western blot (A) and cyclin A expression was quantified (B).
determination of cyclin A expression, since cyclin A is expressed in late G1 prior to DNA
synthesis (Schulze et al., 1995). The western blot in figure 5A shows that during the ongoing
cell cycle cyclin A is a little expressed at 4h after mitosis, which represents mid/late G1 (fig.
1A), while at 6h, in early S phase, and at 8h, in S phase, a significant increase in cyclin A is
observed. These results were evaluated by quantification of the bands and presented as a
percentage of cyclin A expressed at 8h after mitosis (fig. 5B). 
Incubating synchronous N2A cells from 0 or 2h after mitosis with NDGA and left
to incubate until 8h, expressed cyclin A only to a low extent, as compared to cyclin A
expression in control cells at 8h (fig. 6A). The densitrometrical evaluations of the blots show
that cyclin A expression of NDGA treated cells at 0 or 2h did not reach the expression
present at 8h after mitosis (fig. 6B), but remained at the level present at 4h after mitosis of
normal cycling cells (fig. 5B). Thus demonstrating that the cells are arrested in G1.
Similarly, treating cells from 4 or 6h after mitosis with NDGA and analysing cyclin A at 8h
did not result in a full expression as compared to control cells at 8h (fig. 6). Cyclin A
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Figure 6. Lipoxygenase inhibition results in cell cycle arrest. Synchronised N2A cells were left
untreated or were incubated with NDGA (10 µM) from 0, 2, 4 and 6h after mitosis and harvested at
8h after mitosis. Thereafter, 1x105 cells were used for electrophoresis and cyclin A was analysed on
western blot (A). Quantification of cyclin A expression of cells incubated with NDGA, as percentage
of untreated cells at 8h after mitosis.
expression remained at the level present at 6h of untreated cycling cells, as can also be
drawn from the densitometrical evaluations (fig. 6B versus 5B). To more specifically
examine cPLA2 mediated regulation of G1/S phase progression, synchronous cells were
treated with ATK at different hours after mitosis whereafter arachidonic acid (25 µM) was
added back. At 8h after mitosis [3H]-thymidine incorporation was measured but no increase
in DNA synthesis was measured as compared to ATK treated cells (data not shown). Also
no increase was measured when using higher or lower concentrations of arachidonic acid.
However, arachidonic acid can be broken down in the β-oxidation to generate energy or
reacylated into phospholipids by iPLA2. Therefore, similar experiments were performed in
which lipoxygenase was inhibited with NDGA at different hours after mitosis. One or ten
µM of 5(S)-, 12(S)-, 15(S)-HpETE or 15(S)-HETE was added back, but no increase in [3H]-
thymidine incorporation was measured as compared to NDGA treated cells. These data
demonstrate that lipoxygenase inhibition in early G1 results in G1 phase arrest which, in our
experimental set- up, cannot be overcome by the first synthesised products of lipoxygenase,
and that lipoxygenase may also be involved in S phase progression.
Effect of cPLA2 and lipoxygenase inhibition on S phase progression.
Since cPLA2 activity during the cell cycle is high in S phase, we examined the
possible role of cPLA2 during the S phase. Therefore, each hour after mitosis, the [
3H]-
thymidine incorporation was measured as a control, and ATK was added at 6h after mitosis,
which is in S phase, to inhibit cPLA2 activity. No inhibition in [
3H]-thymidine incorporation
was observed (fig. 7 triangles), as compared to control cells (fig. 7, diamonds), showing that
cPLA2 activity in S phase in not necessary for DNA synthesis.
Next, we investigated whether lipoxygenase products play a role in S phase
progression. Therefore, NDGA was added at 3 and 5.30h after mitosis, and [3H]-thymidine
incorporation measurements were started for different time periods. As shown in figure 8,
3h after mitosis is still in the G1 phase (triangles) of the cell cycle, while at 5.30 the cells
are starting to progress through S phase (squares). When inhibiting lipoxygenase at 3h, a full
inhibition in the [3H]-thymidine incorporation was observed, showing that the cells are not
able to progress into S phase any longer. These data are in agreement with the previous
results of figure 6 in that inhibition of lipoxygenase in early G1 resulted in G1 phase arrest.
Furthermore, the addition of NDGA at 5.30h resulted in a complete inhibition in DNA
synthesis that was also confirmed by cyclin A expression (fig. 6), thus demonstrating the
importance of lipoxygenase products in the progression through S phase.
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Figure 7. cPLA2 activity is necessary for S phase progression. ATK (10 µM) was added to half of
the cells at 6h (triangles) after mitosis. After 30 min [3H]-thymidine (1 µCi/well) was added to both
untreated and ATK treated cells and 15 min later [3H]-thymidine incorporation was measured at the
indicated times after mitosis as described in Materials and Methods. Data are represented as means ±
SD (n=3).
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Figure 8. Lipoxygenase is required for S phase progression. At 3 (triangles) and 5.30h (squares)
after mitosis NDGA (10 µM) was added to the cells. After 30 min [3H]-thymidine (1 µCi/well) was
added to both untreated and NDGA treated cells and 15 min later [3H]-thymidine incorporation was
measured at the indicated times after mitosis as described in Materials and Methods. Data are
represented as means ± SD (n=3).
Discussion
Although previous studies demonstrated that PLA2 inhibition reduced cell
proliferation (Adachi et al., 1996; Martinez et al., 1997; Korystov Yu et al., 1998), the
present study is the first to show that cPLA2 activity at distinct periods in the cell cycle is
required for cell cycle progression. By using [3H]-thymidine incorporation as a marker for
DNA synthesis and progression from G1 to S phase, inhibition of cPLA2 in early G1, using
ATK resulted in a reduced DNA synthesis. This reduction was measured only when cPLA2
was inhibited until 2-3h after mitosis. Interestingly, after 2-3h the small increase in cPLA2
activity during the G1 phase occurs (van Rossum, et al., 2001). Inhibition of cPLA2 at 4h,
or at 6h, which is in G1 or S phase, respectively, did not result in a reduced DNA synthesis.
In addition, similar results were obtained with the non-specific PLA2 inhibitor, 4-BPB.
Manoalide only slightly reduced DNA synthesis at 2h and BEL at 2 and 4h, the latter
reduction might be the result of phosphatidate phosphohydrolase inhibition (Balsinde &
Dennis, 1996). These data show that in N2A cells, neither iPLA2 nor sPLA2 play an
important role in cell cycle progression. In N2A cells the activity of cPLA2 in mid/late G1
phase is important for cell cycle progression into S phase, while cPLA2 activity in S phase
is not required for DNA synthesis. 
Since cPLA2 activity was required for G1/S phase progression we evaluated
whether this inhibition resulted in cell cycle arrest. The total cell number of synchronised
N2A cells after a 24h treatment with ATK was comparable to untreated cells and moreover,
was increased to the total number of cells present at 8h. This shows that the cells have
completed their cell cycle, and may result in an increased doubling time of the ATK treated
cells. It has been previously demonstrated that proliferation of asynchronous human
coronary artery vascular smooth muscle cells growing to confluency was inhibited by ATK,
but no phase-specific arrest of the cell cycle was observed (Anderson et al., 1997). We also
find that, although cPLA2 activity is required for G1/S phase progression, the cells do
complete their cell cycle, while cPLA2 activity was still inhibited after a 24h treatment of
ATK. It is, however, also possible that cPLA2 function is taken over by other enzymes, like
the sPLA2s, which then become active to finally generate the arachidonic acid that is
necessary for progression through the cell cycle. Redundancy of PLA2 enzymes has been
observed in P388D1 macrophages in which a transient accumulation of arachidonic acid
produced by cPLA2 resulted in phospholipid hydrolysis which was probably mediated by
activated sPLA2 (Balsinde & Dennis, 1996).
The mechanism by which cPLA2 influences cell cycle progression remains to be
determined. Cyclooxygenase inhibitors had no effect on cell cycle progression into S phase,
indicating that the cPLA2-dependent progression is not mediated by arachidonic acid
metabolites converted by cyclooxygenase. However, our findings demonstrate that
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lipoxygenase is involved in cell cycle progression. Since the lipoxygenase inhibitors, caffeic
acid and NDGA, respectively partially and completely inhibited DNA synthesis when added
in early G1, which was not due to cytotoxic effects of the inhibitors (data not shown).
Additionally, cells in which lipoxygenase was inhibited from 3h after mitosis did not result
in DNA synthesis (fig. 8). This was also confirmed by the low expression of cyclin A in cells
incubated with NDGA from 0 or 2h after mitosis as compared to control cells. These data
show an arrest in G1 phase of lipoxygenase inhibited cells. In line with this are the results
of Korystov et al. (1998) who demonstrated a suppression of cell proliferation of
lympholeukemic cells with NDGA, also by blocking the G1/S transition. However, the
mechanism by which NDGA blocks the G1/S transition is still unknown. Re-addition of
arachidonic acid or the lipoxygenase metabolites 5(S)-, 12(S)- or 15(S)-HpETE, or 15(S)-
HETE at various times and concentrations after mitosis could not overcome the inhibitory
effect of ATK or NDGA. It might be that NDGA inhibits a protein through the inhibition of
lipoxygenase, which is required for S phase entry. It has been reported that lipoxygenase
was involved in mediating arachidonic acid-induced p42/44MAPK activation (Rao et al.,
1994; Chang & Wang, 2001). However, lipoxygenase inhibition by NDGA did not affect
p42/44MAPK phosphorylation in N2A cells (data not shown), indicating that lipoxygenase
exerts its effects downstream of p42/44MAPK. Since eicosanoids are synthesised on demand
at the time and location needed, it is possible that the concentrations used are still to high or
to low. The products may even not reach the location at which they act, like for arachidonic
acid that, next to its action, can be broken down to generate energy or can be re-incorporated
into phospholipids.
Lipoxygenase inhibition in early S phase also resulted in a block in DNA synthesis.
Furthermore, cells in which lipoxygenase was inhibited from 4 or 6h after mitosis were
arrested in early S phase as judged by cyclin A expression. Taken together, cPLA2 activity
in G1 phase is necessary for cell cycle progression into S phase, while cPLA2 activity in S
phase is not involved in DNA synthesis. Furthermore, lipoxygenase is required for both
G1/S and S phase progression. 
Acknowledgments
We would like to thank Prof. Dr. G. A. Veldink and G. van Zadelhoff for their
helpful discussions and kindly providing the lipoxygenase products. We thank Pieter
Neerincx for his technical assistance. This work was supported by the Council for Chemical
Sciences of the Netherlands Organization for Scientific Research (CW-NWO) (Grant 700-
30-022). 
124
Chapter 5
References
Ackermann, E.J., Conde-Frieboes, K. & Dennis, E.A. (1995). Inhibition of macrophage Ca2+-
independent phospholipase A2 by bromoenol lactone and trifluoromethyl ketones. J. Biol. Chem. 270,
445-450.
Adachi, T., Nakashima, S., Saji, S., Nakamura, T. & Nozawa, Y. (1996). Mitogen-activated protein
kinase activation in hepatocyte growth factor-stimulated rat hepatocytes: involvement of protein
tyrosine kinase and protein kinase C. Hepatology 23, 1244-1253.
Aktas, H., Cai, H. & Cooper, G.M. (1997). Ras links growth factor signaling to the cell cycle
machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1. Mol. Cell. Biol. 17, 3850-3857.
Anderson, K.M., Roshak, A., Winkler, J.D., McCord, M. & Marshall, L.A. (1997). Cytosolic 85-
kDa phospholipase A2-mediated release of arachidonic acid is critical for proliferation of vascular
smooth muscle cells. J. Biol. Chem. 272, 30504-30511.
Balsinde, J. & Dennis, E.A. (1996). Bromoenol lactone inhibits magnesium-dependent phosphatidate
phosphohydrolase and blocks triacylglycerol biosynthesis in mouse P388D1 macrophages. J. Biol.
Chem. 271, 31937-31941.
Balsinde, J. & Dennis, E.A. (1996). Distinct roles in signal transduction for each of the phospholipase
A2 enzymes present in P388D1 macrophages. J. Biol. Chem. 271, 6758-6765.
Boonstra, J., Mummery, C.L., Tertoolen, L.G., van der Saag, P.T. & de Laat, S.W. (1981). Cation
transport and growth regulation in neuroblastoma cells. Modulations of K+ transport and electrical
membrane properties during the cell cycle. J. Cell. Physiol. 107, 75-83.
Chang, J., Musser, J.H. & McGregor, H. (1987). Phospholipase A2: function and pharmacological
regulation. Biochem. Pharmacol. 36, 2429-2436.
Chang, L.C. & Wang, J.P. (2001). Signal transduction pathways for activation of extracellular signal-
regulated kinase by arachidonic acid in rat neutrophils. J. Leukoc. Biol. 69, 659-665.
Cheng, M., Sexl, V., Sherr, C.J. & Roussel, M.F. (1998). Assembly of cyclin D-dependent kinase
and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). Proc. Natl.
Acad. Sci. USA 95, 1091-1096.
Copeland, R.A., Williams, J.M., Giannaras, J., Nurnberg, S., Covington, M., Pinto, D., Pick, S.
& Trzaskos, J.M. (1994). Mechanism of selective inhibition of the inducible isoform of prostaglandin
G/H synthase. Proc. Natl. Acad. Sci. USA 91, 11202-11206.
Dethlefsen, S.M., Shepro, D. & DAmore, P.A. (1994). Arachidonic acid metabolites in bFGF-,
PDGF-, and serum-stimulated vascular cell growth. Exp. Cell Res. 212, 262-273.
125
cPLA2 , lipoxygenase and cell cycle progression
Dirks, P.B. & Rutka, J.T. (1997). Current concepts in neuro-oncology: the cell cyclea review.
Neurosurgery 40, 1000-1015.
Grazia Cifone, M., Roncaioli, P., Cironi, L., Festuccia, C., Meccia, A., DAló, S., Botti, D. &
Santoni, A. (1997). NKR-P1A stimulation of arachidonate-generating enzymes in rat NK cells is
associated with granule release and cytotoxic activity. J. Immunol. 159, 309-317.
Heasley, L.E., Thaler, S., Nicks, M., Price, B., Skorecki, K. & Nemenoff, R.A. (1997). Induction
of cytosolic phospholipase A2 by oncogenic Ras in human non-small cell lung cancer. J. Biol. Chem.
272, 14501-14504.
Hope, W.C., Welton, A.F., Fiedler-Nagy, C., Batula-Bernardo, C. & Coffey, J.W. (1983). In vitro
inhibition of the biosynthesis of slow reacting substance of anaphylaxis (SRS-A) and lipoxygenase
activity by quercetin. Biochem. Pharmacol. 32, 367-371.
Hsi, L.C. & Eling, T.E. (1998). Inhibition of EGF-dependent mitogenesis by prostaglandin E2 in
Syrian hamster embryo fibroblasts. Prostaglandins Leukot. Essent. Fatty Acids 58, 271-281.
Hulleman, E., Bijvelt, J.J.M., Verkleij, A.J., Verrips, C.T. & Boonstra, J. (1999). Nuclear
translocation of mitogen-activated protein kinase p42MAPK during the ongoing cell cycle. J. Cell.
Physiol. 180, 325-333.
Hulleman, E. & Boonstra, J. (2001). Regulation of G1 phase progression by growth factors and the
extracellular matrix. Cell. Mol. Life Sci. 58, 80-93.
Jacobson, P.B., Marshall, L.A., Sung, A. & Jacobs, R.S. (1990). Inactivation of human synovial
fluid phospholipase A2 by the marine natural product, manoalide. Biochem. Pharmacol. 39, 1557-
1564.
Korystov Yu, N., Shaposhnikova, V.V., Levitman, M., Kudryavtsev, A.A., Kublik, L.N.,
Narimanov, A.A. & Orlova, O.E. (1998). The effect of inhibitors of arachidonic acid metabolism on
proliferation and death of tumor cells. FEBS Lett. 431, 224-226.
Koshihara, Y., Neichi, T., Murota, S., Lao, A., Fujimoto, Y. & Tatsuno, T. (1984). Caffeic acid is
a selective inhibitor for leukotriene biosynthesis. Biochim. Biophys. Acta 792, 92-97.
Laneuville, O., Breuer, D.K., DeWitt, D.L., Hla, T., Funk, C.D. & Smith, W.L. (1994). Differential
inhibition of human prostaglandin endoperoxide H synthases- 1 and -2 by nonsteroidal anti-
inflammatory drugs. J. Pharmacol. Exp. Ther. 271, 927-934.
Martinez, J., Sanchez, T. & Moreno, J.J. (1997). Role of prostaglandin H synthase-2-mediated
conversion of arachidonic acid in controlling 3T6 fibroblast growth. Am. J. Physiol. 273, C1466-1471.
Nigg, E.A. (1995). Cyclin-dependent protein kinases: key regulators of the eukaryotic cell cycle.
Bioessays 17, 471-480.
126
Chapter 5
Pagès, G., Lenormand, P., LAllemain, G., Chambard, J.C., Meloche, S. & Pouysségur, J. (1993).
Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation. Proc.
Natl. Acad. Sci. USA 90, 8319-8323.
Piomelli, D. (1993). Arachidonic acid in cell signaling. Curr. Opin. Cell Biol. 5, 274-280.
Rao, C.V., Desai, D., Simi, B., Kulkarni, N., Amin, S. & Reddy, B.S. (1993). Inhibitory effect of
caffeic acid esters on azoxymethane-induced biochemical changes and aberrant crypt foci formation
in rat colon. Cancer Re. 53, 4182-4188.
Rao, G.N., Baas, A.S., Glasgow, W.C., Eling, T.E., Runge, M.S. & Alexander, R.W. (1994).
Activation of mitogen-activated protein kinases by arachidonic acid and its metabolites in vascular
smooth muscle cells. J. Biol. Chem. 269, 32586-32591.
Reed, S.I. (1997). Control of the G1/S transition. Cancer Surv. 29, 7-23.
Reich, R. & Martin, G.R. (1996). Identification of arachidonic acid pathways required for the
invasive and metastatic activity of malignant tumor cells. Prostaglandins 51, 1-17.
Roovers, K., Davey, G., Zhu, X., Bottazzi, M.E. & Assoian, R.K. (1999). Alpha5beta1 integrin
controls cyclin D1 expression by sustaining mitogen-activated protein kinase activity in growth factor-
treated cells. Mol. Biol. Cell 10, 3197-3204.
Sa, G. & Fox, P.L. (1994). Basic fibroblast growth factor-stimulated endothelial cell movement is
mediated by a pertussis toxin-sensitive pathway regulating phospholipase A2 activity. J. Biol. Chem.
269, 3219-3225.
Salari, H., Braquet, P. & Borgeat, P. (1984). Comparative effects of indomethacin, acetylenic acids,
15-HETE, nordihydroguaiaretic acid and BW755C on the metabolism of arachidonic acid in human
leukocytes and platelets. Prostaglandins Leukot. Med. 13, 53-60.
Schulze, A., Zerfass, K., Spitkovsky, D., Middendorp, S., Bergès, J., Helin, K., Jansen-Dürr, P. &
Henglein, B. (1995). Cell cycle regulation of the cyclin A gene promoter is mediated by a variant E2F
site. Proc. Natl. Acad. Sci. USA 92, 11264-11268.
Shappell, S.B., Gupta, R.A., Manning, S., Whitehead, R., Boeglin, W.E., Schneider, C., Case, T.,
Price, J., Jack, G.S., Wheeler, T.M., Matusik, R.J., Brash, A.R. & Dubois, R.N. (2001). 15S-
Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits
proliferation in PC3 prostate carcinoma cells. Cancer Res. 61, 497-503.
Sherr, C.J. (1995). D-type cyclins. Trends Biochem. Sci. 20, 187-190.
Sherr, C.J. & Roberts, J.M. (1995). Inhibitors of mammalian G1 cyclin-dependent kinases. Genes
Dev. 9, 1149-1163.
127
cPLA2 , lipoxygenase and cell cycle progression
Sivaraman, V.S., Wang, H., Nuovo, G.J. & Malbon, C.C. (1997). Hyperexpression of mitogen-
activated protein kinase in human breast cancer. J. Clin. Invest. 99, 1478-1483.
Street, I.P., Lin, H.K., Laliberté, F., Ghomashchi, F., Wang, Z., Perrier, H., Tremblay, N.M.,
Huang, Z., Weech, P.K. & Gelb, M.H. (1993). Slow- and tight-binding inhibitors of the 85-kDa
human phospholipase A2. Biochemistry 32, 5935-5940.
Trimble, L.A., Street, I.P., Perrier, H., Tremblay, N.M., Weech, P.K. & Bernstein, M.A. (1993).
NMR structural studies of the tight complex between a trifluoromethyl ketone inhibitor and the 85-
kDa human phospholipase A2. Biochemistry 32, 12560-12565.
van Rossum, G.S.A.T., Vlug, A.S., van den Bosch, H., Verkleij, A.J. & Boonstra, J. (2001).
Cytosolic phospholipase A2 activity during the ongoing cell cycle. J. Cell. Physiol. 188, 321-328.
Zupan, L.A., Weiss, R.H., Hazen, S.L., Parnas, B.L., Aston, K.W., Lennon, P.J., Getman, D.P. &
Gross, R.W. (1993). Structural determinants of haloenol lactone-mediated suicide inhibition of canine
myocardial calcium-independent phospholipase A2. J. Med. Chem. 36, 95-100.
128
Chapter 5
Summarising Discussion
C h a p  t e r6
130
Chapter 6
Signal transduction pathways activating cPLA2 .
The studies described in chapters 2, 3 and 4 show that cPLA2 is activated through
different signal transduction pathways depending on the stimulus in the extracellular
environment. In response to EGF, cPLA2 is predominantly activated through PKC-MEK-
p42/44MAPK, while serum-induced cPLA2 activity is mainly mediated via the Raf-MEK-
p42/44MAPK pathway. In contrast, direct activation of PKC by phorbol ester (PdBu) did not
result in increased cPLA2 activity, while p42/44
MAPK was activated via Raf-MEK and
through MEK. Activation of cPLA2 by the oxidant H2O2 is partly mediated via Raf-MEK-
p42/44MAPK and partly through a phosphorylation-independent mechanism involving
peroxidised phospholipids. 
These results suggest that activation of cPLA2 is not only governed by post-
translational modifications but, more importantly, by localisation of the signal transduction
components at a certain time that determines whether cPLA2, at which place and what time
cPLA2 will be activated. Cells appear to respond to diverse stimuli resulting in the activation
of different signal transduction pathways which might lead to different cellular processes,
such as differentiation, proliferation and apoptosis. This shows that cells are very flexible in
adapting to changes in the extracellular environment. This is illustrated by an increasing
number of evidence indicating that p42/44MAPK can be targeted to specific sites within the
cell. For example, p42/44MAPK is able to associate with the cytoskeleton, is present at
different locations in and phases of mitotic cells, can phosphorylate several proteins in the
cytoplasm, or translocate to the nucleus to activate transcription factors (reviewed in
Schaeffer & Weber, 1999; Hulleman & Boonstra, 2001). Nerve growth factor stimulation of
PC12 cells resultes in a sustained activation of p42/44MAPK, leading to exit of the cell cycle
and differentiation of the cells. In contrast, EGF induces a transient p42/44MAPK activation
leading to proliferation of the cells (reviewed in Marshall, 1995).
We propose in serum- and EGF-activated Her14 cells, activation of p42/44MAPK
throughout the entire cell, since the EGF receptor is still active when internalised in
endosomes (Lai et al., 1989; Wada et al., 1992). Additionally, compartimentalisation of
phosphorylated EGF receptors with Shc proteins, but also active Raf and MEK in early
endosomes have been shown (Baass et al., 1995; Pol et al., 1998). The activated p42/44MAPK
then phosphorylates and activates cPLA2. In contrast, activation of PKC by PdBu probably
occurs at the plasmamembrane, because of the hydrophobic nature of PdBu. Thereupon
translocation of PKC to the membrane occurs, resulting in p42/44MAPK activation near the
plasmamembrane. However, no activation of cPLA2 was observed, likely because
p42/44MAPK and cPLA2 are not present at exactly the same place. This implies the activation
of another population of p42/44MAPK, which might indeed be the case, since PdBu activates
another set of PKC isoforms, in contrast to EGF and serum stimulation of Her14 cells
(chapter 2). Exposing cells to H2O2 can activate cPLA2 within the entire cell at membranes.
It has been shown that H2O2 inhibits internalisation of receptors, like for the EGF and
growth hormone receptor (Strous et al., 1996; de Wit et al., 2001). Also the ubiquitination
of the receptors is inhibited, therefore, the receptor will not be degraded by the proteasome
pathway and thus will remain active. Because of this, signalling molecules are activated at
the plasmamembrane or any other membrane within the cell. This results in cPLA2
activation in the vicinity of the membranes, whereupon cPLA2 translocates to the membrane
due to H2O2-induced peroxidation of membrane lipids.  Arachidonic acid release from the
membrane is facilitated due to these peroxidised lipids thereby prolonging cPLA2 activity,
which it is usually subject to product inhibition (Reynolds et al., 1993; Bayburt & Gelb,
1997; Burke et al., 1999). Over time, cPLA2 has to be dephosphorylated to inactivate the
enzyme, probably by phosphatases. Phosphatases can be inactivated through the action of
H2O2 (Sullivan et al., 1994; Caselli et al., 1998), leaving cPLA2 active for a longer period
of time. 
cPLA2 in Her14 cells is predominantly localised as clusters near all organellar
membranes, except for the golgi apparatus (Bunt et al., 1997). No translocation of cPLA2 to
(particular) membranes was observed in EGF- as well as in A23187-stimulated cells. We
have proposed a cluster-monomer model in which these clusters represent the inactive form
of cPLA2 from which active monomers can be recruited upon stimulation (Bunt et al.,
2000), that might occur via phosphorylation of cPLA2 by p42/44
MAPK. This means that, in
principle, cPLA2 can be activated at every membrane within the cell, but the presence of
p42/44MAPK to phosphorylate cPLA2 is a prerequisite. As described above, p42/44
MAPK and
other components of the signal transduction pathways differ in localisation, depending on
the stimuli and therefore, is cPLA2 only activated at certain locations within the cell,
otherwise the cell will be destroyed. Thus, to acquire a good insight in the cellular functions
of cPLA2, one should actually focus on the localisation of active cPLA2 monomers.
Cell cycle regulation.
The cellular localisation of signal transduction components determines whether
cPLA2 will be activated. However, understanding the function of cPLA2 in cells requires
also knowledge of the activation of cPLA2 in a temporal manner. Therefore, the activity of
cPLA2 was investigated during the ongoing cell cycle as described in chapters 4 and 5.
cPLA2 activity was high in mitosis, decreasing afterwards, peaking at mid/late G1 and a
subsequent increase in activity was measured following the G1/S transition. These changes
in cPLA2 activity were not due to differences in cPLA2 protein expression, but due to
p42/44MAPK mediated phosphorylation of the enzyme. Inhibition of cPLA2 in early G1
phase resulted in a reduced progression into S phase.  
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The high activity of cPLA2 in mitotic cells suggests a function for cPLA2 during
M phase. At prometaphase the spindle microtubules have to interact with the chromosomes.
To accomplish this, the nuclear envelope has to be broken down that might be mediated by
cPLA2. Immunofluorescence studies showed that a small pool of total p42/44
MAPK is also
active during M phase where it is associated with tubulin and MAP-2 (Morishima-
Kawashima & Kosik, 1996). Interestingly, it was reported that cPLA2 in mitotic cells
obtained by colcemid treatment was suppressed compared to interphase cells (Berlin &
Preston, 1995). This seems to be conflicting; however, colcemid disrupts microtubuli
leaving p42/44MAPK and cPLA2 inactive. p42/44
MAPK is also inactive when cyclin B is
degraded, to exit from mitosis, which might result in the decrease in cPLA2 activity after
mitosis.
The next period of increased cPLA2 activity is during mid/late G1. In this period
p42MAPK was shown to translocate to the nucleus (Hulleman et al., 1999), and cPLA2
activation was mediated by p42/44MAPK. This suggests that cPLA2 is activated at the nuclear
envelope, or is also translocated to the nucleus, since the arachidonic acid released by cPLA2
is involved in G1/S progression. Lipoxygenase inhibition in early G1 arrested N2A cells in
G1. This indicates that the arachidonic acid released in mid/late G1 is converted by
lipoxygenase into lipoxygenase products, which are actually involved in G1/S phase
progression. However, the precise mechanism remains to be dissolved.
Lipoxygenase inhibition in S phase was demonstrated to block DNA synthesis.
This process is probably not mediated through the conversion of arachidonic acid released
by cPLA2, since cPLA2 inhibition in S phase did not result in a reduced DNA synthesis. In
addition, also inhibition of cPLA2 at 4 or 6h after mitosis did not reduce DNA synthesis,
although this is not completely clear. cPLA2 and especially lipoxygenase play an important
role in the progression of the cell cycle. This is supported by the observation that
lipoxygenase and cPLA2 are overexpressed in cancer cells (Funk, 1996; Heasley et al.,
1997; Ikawa et al., 1999; Shappell et al., 2001). Thus it is important to understand the
function and mechanism by which lipoxygenase and cPLA2 regulate cell cycle progression
for the development and therapeutic use of anti-cancer drugs.
Phospholipase A2 and reactive oxygen species in cellular injury
At present, it is commonly known that ROS, such as O2
¯ and H2O2, are produced
in a variety of cells in response to growth factors, agonists of G-protein-coupled receptors
(GPCRs) and cytokines, and are required for the mitogenic response. For example, EGF
(Bae et al., 1997), PDGF (Sundaresan et al., 1995), thrombin (Patterson et al., 1999),
lysophosphatidic acid (Sekharam et al., 2000), Interleukin-1, Interferon-γ (Krieger-Brauer
& Kather, 1995) and TNF-α (Lo & Cruz, 1995). Upon the release of H2O2, the receptor
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becomes tyrosine phosphorylated, resulting in complex formation with signalling
molecules, such as Shc, Grb2 and sos (Rao, 1996). Macrophages and neutrophils also
produce ROS to destroy microorganisms in the extracellular environment. An inappropriate
release of these agents into the surrounding tissues and cells can result in cellular injury.
This depends on the concentration and duration of the stress, on the cell type and on the cell
cycle phase of the cells. For instance brain function and kidney epithelial cells are highly
sensitive to ROS (Sussman & Bulkley, 1990; Schubert et al., 1995; Sapirstein et al., 1996).
On the other hand, astroglial cells as well as Her14 cells appear to be more resistant to
oxidants (Café et al., 1995), whereas CHO cells arrest in G1 and in G2/M phase (Clopton
& Saltman, 1995). 
PLA2 and ROS have been implicated in various forms of cellular injury. The
increase in cPLA2 activity is suggested to occur through a mechanism as discussed earlier,
in which cPLA2 activity is increased due to phosphorylation of the enzyme and due to
peroxidation of membrane lipids. Because of this increase in (c)PLA2 activity and the
concomitant release of arachidonic acid, it was first thought that (c)PLA2 would have a
repair function by releasing peroxidised arachidonic acid. However, in many of these
studies, no discrimination was made between oxidised and unoxidised arachidonic acid. It
was shown later that cPLA2 still preferentially liberates unoxidised over oxidised
arachidonic acid (Nigam & Schewe, 2000), thus indicating that cPLA2 is not involved in a
repair function. Recent studies show the involvement of cPLA2 in cell death (Wissing et al.,
1997; de Valck et al., 1998; Hornfelt et al., 1999). The injured cells have to be broken down,
and although the precise mechanism of action is unknown, it might involve a massive
activation of cPLA2.
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Samenvatting
Samenvatting
Het menselijk lichaam is opgebouwd uit zeer veel cellen. Deze cellen bestaan uit
verschillende kamertjes (organellen), die in het celvocht (cytoplasma) liggen dat omgeven
wordt door een muur (de celmembraan). De organellen hebben allemaal hun eigen functie.
Zo is er de kern waarin het erfelijk materiaal (het DNA) ligt opgeslagen en de mitochondriën
zorgen voor de energieproduktie in de cel. In de lysosomen worden niet meer
functionerende organellen en grote molekulen afgebroken, terwijl de peroxisomen zorgen
voor de afbraak van verschillende vetten. Nieuwe eiwitten worden gemaakt in het
endoplasmatisch reticulum die daarna naar het golgi-apparaat gaan waar de eiwitten
gesorteerd en gelabeld worden zodat ze op de goede plek in de cel terechtkomen. Al deze
organellen zijn omgeven door een membraan dat voornamelijk opgebouwd is uit vetachtige
molekulen, fosfolipiden genaamd. Fosfolipiden bestaan uit een ruggegraat waaraan op de
1- (sn-1) en 2- (sn-2) plaats een vetzuurstaart vastzit en op de 3e plaats bevindt zich de
kopgroep.
In de cel zijn bepaalde enzymen (eiwitten die een reaktie sneller kunnen laten
verlopen) die het vetzuur van de 2-plaats van membraan fosfolipiden vrijmaken
(hydrolyseren), dat zijn de fosfolipases A2. Dit hydrolyseren is heel belangrijk wanneer het
vrije vetzuur arachidonzuur is, omdat arachidonzuur bij veel fysiologische processen en
ziektes betrokken is, zoals bij ontstekingen, neurodegeneratieve ziektes als Alzheimer en
Parkinson, het doodgaan van cellen, het doorgeven van boodschappen in een cel (signaal
transductie) en kanker. Arachidonzuur wordt preferentieel vrijgemaakt door het cytosolische
fosfolipase A2 (cPLA2) dat 85 kDa groot is. De activiteit van het cPLA2 moet goed
gereguleerd worden in de cel, anders ontstaan er pathologische verschijnselen. cPLA2 kan
alleen arachidonzuur vrijmaken als het aan membranen gebonden is, omdat hier zich het
arachidonzuur bevindt. Hydrolysering van arachidonzuur kan alleen als het cPLA2 actief is,
want in een inactieve toestand bevindt het cPLA2 zich in het cytoplasma. cPLA2 activiteit
wordt verhoogd wanneer een fosfaatgroep wordt geplaatst op het aminozuur serine nummer
727 en/of 505 door een signaal transductie eiwit behorende tot de MAPK familie, meestal
p42/44MAPK. Daarna kan onder invloed van een verhoogde calcium concentratie in de cel
het cPLA2 aan membranen binden en vervolgens arachidonzuur vrijmaken. 
In hoofdstuk 1 worden de karakteristieken van het cPLA2 beschreven, wat er al
bekend is over de regulatie van cPLA2 en  hoe het proces van celdeling is gereguleerd.
Verder wordt er beschreven wat het belang is van cPLA2, en enzymen die het arachidonzuur
kunnen omzetten, voor ontwikkeling en groei, en in ziektes.
In hoofdstuk 2 is beschreven hoe het cPLA2 wordt geactiveerd als cellen van
buitenaf worden gestimuleerd met verschillende signalen (prikkels), bijvoorbeeld
groeifactoren. Deze signalen gaan op een voor hen specifieke antenne (receptor) zitten die
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zich in de membraan bevindt. Daarna wordt dit signaal in de cel doorgegeven via allerlei
signaal transductie eiwitten totdat het uiteindelijke doeleiwit geactiveerd is. Cellen die we
eerst in een rusttoestand gebracht hadden, werden vervolgens met verschillende
groeifactoren gestimuleerd. Ook is gekeken naar de regulatie van cPLA2 in rustende of
constant groeiende cellen. Met behulp van remmers voor verschillende signaal transductie
eiwitten werd gevonden dat het cPLA2 via verschillende routes kan worden geactiveerd,
zoals zo vele wegen naar Rome leiden. Zo blijkt cPLA2 in rustende cellen geactiveerd via
de Raf-MEK-p42/44MAPK signaal transductie route, terwijl deze route in groeiende cellen
ook actief is maar dit niet leidt tot cPLA2 activering. In rustende cellen die gestimuleerd
werden met serum werd voornamelijk de Raf-MEK-p42/44MAPK route actief en voor een
klein gedeelte de PKC-MEK-p42/44MAPK route. Beide routes resulteerde in verhoogde
cPLA2 activiteit. Als de cellen met epidermale groeifactor gestimuleerd worden, wordt
cPLA2 hoofdzakelijk via de PKC-MEK-p42/44
MAPK route geactiveerd en voor een heel
klein gedeelte via de Raf-MEK-p42/44MAPK route. Echter directe activatie van PKC door
cellen phorbol ester te geven, leidt wel tot p42/44MAPK activatie zowel via de PKC-MEK als
de PKC-Raf-MEK route, alleen leidt  dit niet tot cPLA2 activering. 
In hoofdstuk 3 is gekeken of cPLA2, en hoe cPLA2 geactiveerd wordt wanneer
rustende cellen blootgesteld worden aan oxidatieve stress door waterstofperoxide (H2O2)
aan de cellen te geven. We spreken van oxidatieve stress als cellen worden blootgesteld aan
een verhoogde concentratie zuurstofradicalen. Zuurstofradicalen zijn tussenprodukten die
worden gevormd bij de omzetting van zuurstof naar water welke erg reaktief zijn. Deze
zuurstofradicalen kunnen reageren met (en daarmee schade aanrichten aan) DNA, lipiden en
eiwitten. Cellen hebben hiertegen afweermechanismen. Als deze mechanismen niet goed
werken, of er is een overproductie van zuurstofradicalen ontstaan dan leidt dit tot oxidatieve
stress. Oxidatieve stress speelt een rol bij zowel cellulaire processen als celdeling, celdood
en celschade alswel bij arteriosclerose en neurodegeneratieve ziektes. Onder normale
omstandigheden zijn kleine hoeveelheid zuursofradicalen nodig voor een goed verloop van
signaal transductie routes. Wij vonden dat cPLA2 snel geactiveerd kan worden door H2O2
op een concentratie en tijdsafhanklijke manier. H2O2 stimulatie van rustende cellen
resulteerde in een gedeeltelijke activering van het cPLA2 door fosforylatie via de Raf-MEK-
p42/44MAPK signaal transductie route. Verder werd cPLA2 ook gedeeltelijk geactiveerd via
een fosforylatie-onafhankelijke mechanisme. Dus, in H2O2 geactiveerde cellen gebeurt
cPLA2 activering op een andere manier dan in groeifactor gestimuleerde cellen. Zoals eerder
gezegd is voor cPLA2 activiteit ook calcium nodig om cPLA2 aan de membraan te laten
binden, maar in dit geval was cPLA2 nog steeds actief in de membraan fractie te vinden, ook
als het calcium weggevangen was. Uit de literatuur is bekend dat, in cellen,
zuurstofradicalen lipiden kunnen beschadigen door deze te peroxideren (reactief zuurstof in
de lipiden in te bouwen). Hierdoor treden er veranderingen op in de membranen van de cel,
141
Samenvatting
waardoor het cPLA2 beter bij zijn substraat arachidonzuur kan en dus meer arachidonzuur
kan vrijmaken uit het membraan. Door deze membraanveranderingen is er minder  calcium
nodig om cPLA2 naar de membraan te brengen en is deze binding misschien ook steviger.
Dit alles leidt ertoe dat het cPLA2 naast de activering door fosforylatie extra actief wordt
door H2O2-geïnduceerde veranderingen in de membranen. Uit de resultaten van de
hoofdstukken 2 en 3 volgt dat de route die na een bepaalde stimulatie actief is afhangt van
de plaats van verschillende signaal transductie eiwitten op een bepaald tijdstip in de cel, wat
al dan niet leidt tot cPLA2 activering. Cellen kunnen zich op deze manier sneller aanpassen
aan veranderingen in hun omgeving.
Tot nu toe is de activering van het cPLA2 op één tijdstip bekeken. Om de functie
van het cPLA2 beter te begrijpen moet ook naar de activering van het cPLA2 in de loop van
de tijd bekend zijn. Dit is gedaan door de activiteit te meten gedurende de celcyclus.
Celcyclus is het proces dat leidt tot celdeling welke bestaat uit 4 fasen: de mitose waarin het
verdubbelde DNA verdeeld wordt over de twee nieuw ontstane cellen, de G1 fase, de S fase
waarin het DNA verdubbeld (gerepliceerd) wordt en de G2 fase. De voortgang (progressie)
van de celcyclus  wordt goed gereguleerd. In elke fase checkt de cel of alle factoren optimaal
zijn alvorens de overgang naar de volgende fase te maken. Hierbij zijn bepaalde eiwitten van
belang, de cyclines. Elke fase heeft zo zijn eigen specifieke cyclines die weer met een ander
eiwit, de cycline-afhankelijke kinase (Cdk) een actief complex kunnen vormen. Een
cycline/Cdk complex komt via actieve signaal tranductie routes tot stand, maar kan zelf het
signaal ook weer doorgeven. Als ergens in de route iets ontregeld is, stopt de cel, en
optimaliseert eerst alle factoren alvorens verder te gaan. Wanneer die factoren binnen een
bepaalde tijd niet geoptimaliseerd kunnen worden kan de cel besluiten zelfmoord
(apoptose) te plegen. De cel kan ook dusdanig ontregeld zijn dat het ongeremd kan delen
wat kan leiden tot tumorvorming.
In hoofdstuk 4 is beschreven dat cPLA2 activiteit verandert gedurende de celcyclus.
De activiteit van het cPLA2 is hoog in mitotische cellen en neemt daarna snel af in de vroege
G1 om weer toe te nemen in het midden-late G1. Na de G1/S overgang neemt de activiteit
van het cPLA2 weer sterk toe. De verandering in de activiteit van het cPLA2 werd niet
veroorzaakt door het aantal molekulen cPLA2 (cPLA2 eiwit expressie), maar doordat het
cPLA2 in deze actieve perioden gefosforyleerd was door p42/44
MAPK. 
Vervolgens hebben we in hoofdstuk 5 onderzocht wat de functie van deze
verhoogde cPLA2 activiteits pieken betekenen voor de progressie van de celcylcus.
Celcyclus progressie werd bepaald door de hoeveelheid radioactief gelabeld thymidine te
meten dat ingebouwd wordt in het DNA ([3H]-thymidine incorporatie of DNA synthese). Dit
gebeurt alleen als cellen zich in de S fase bevinden en zo kun je meten of cellen van de G1
naar de S fase gaan. Als de activiteit van cPLA2 vroeg in de G1 fase geremd wordt door ATK
(een gemodificeerd arachidonzuur molekuul) blijkt de DNA synthese met ongeveer 50%
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verminderd te zijn. Dit effect is niet toe te schrijven aan andere leden van de fosfolipase A2
familie. Het vrijgekomen arachidonzuur kan ook omgezet worden door cyclooxygenases tot
onder andere prostaglandines en thromboxanen, of door lipoxygenases tot onder andere
leukotriënen en HETEs. Remming van cyclooxygenases op verschillende tijdstippen in de
G1 resulteerde niet in een remming in DNA synthese. Daarentegen leidde remming van
lipoxygenases wel tot verminderde thymidine incorporatie. Wanneer lipoxygenase vroeg in
de G1 werd geremd stopte de cellen later in de G1 fase. Dus, zowel cPLA2 als lipoxygenase
zijn betrokken bij celcyclus progressie van de G1 naar de S fase. cPLA2 activiteit is ook
verhoogd in de S fase en dus werd onderzocht of cPLA2 ook een rol speelt bij S fase
progressie. Dit bleek niet het geval te zijn, omdat er geen verminderde DNA synthese werd
gemeten wanneer cPLA2 was geremd in cellen die zich in de S fase bevonden. Vervolgens
werden lipoxygenases geremd in cellen die zich vroeg in de S fase bevonden, maar er vond
geen DNA synthese meer plaats. Dit wil zeggen dat de activiteit van cPLA2 in de S fase niet
belangrijk is voor S fase progressie. Het kan wel een andere functie hebben in de S fase of
zelfs later in de celcyclus, maar dat moet nog verder onderzocht worden. Verder blijkt dat
lipoxygenases heel belangrijk zijn voor S fase progressie. 
Tenslotte wordt in hoofdstuk 6 de resultaten van de verschillende hoofdstukken
bediscussieerd. Wat is nu de fysiologische relevantie van al deze resultaten. Het is belangrijk
te weten wat de functie van cPLA2 is. We weten dat cPLA2 overal in de cel aanwezig is en
dus overal geactiveerd kan worden. Om de functie te weten te komen moet er onderzocht
worden hoe cPLA2 gereguleerd wordt en vooral waar het zich in actieve vorm in de cel
bevindt. Verder moet er ook bekend zijn hoe cPLA2 in de tijd wordt geactiveerd. Pas dan
kan er op deze signaal transductie routes ingegrepen worden en kunnen nieuwe specifieke
remmers gemaakt worden met een therapeutisch doel.
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Nawoord
Ja, en dan nu het nawoord. Nou mensen, het wordt eindelijk weer rustig op de 5e
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Verder Henk, bedankt dat je aan me dacht toen deze OIO plek vrijkwam en voor de heldere
samenvattingen van de soms intensieve PLA2 besprekingen. Hopelijk hoef ik niet op rijm je
vragen te beantwoorden, want aan jouw rijmkwaliteiten kan ik niet tippen.
Gertrude, bedankt voor het meedenken en de discussies.
Zonder mijn studenten, Angela, Rinse, Michael en Pieter had ik nooit al dit werk kunnen
doen. Bedankt voor jullie interesse en inzet.
Mijn lab- en kamergenoten Esther, José en Susanna die wellicht wel even hebben moeten
wennen aan al mijn uitspattingen. Fijn dat ik altijd bij jullie terecht kon om te praten over
werk, wanneer ik mijn ei kwijt moest of zomaar voor de gezelligheid. In dit kader denk
ik ook aan de gezellige gesprekken met Yvonne, Hans en Fons.
Bruno en Margo wil ik bedanken voor het immunofluorescentie werk, alleen jammer dat er
niet meer inzat dan alleen testen. 
Ton, Fred en Jan, bedankt voor de gezelligheid op oost 6 waardoor ik weer op de hoogte was
van wat er allemaal op de 6e gebeurde en dat ik, en mijn studenten, daar al die tijd mochten
assayen. Ik zal de buizen schoonmaken!
Antje, bedankt voor het versturen van mijn manuscripten en het snelle regelen van andere
promotie zaken. Ton, jij maakte me altijd aan het lachen met je (on)eerbare voorstellen.
Bedankt voor de bestellingen, de schouderklopjes en de massage.
Verder wil ik familie, vrienden en kennissen bedanken voor de interesse in het wel en wee
van mijn onderzoek. Ook al begrepen jullie niet (altijd) waar ik mee bezig was. Misschien
dat de nederlandse samenvatting wat licht in de duisternis brengt.
Tenslotte Kees. Bedankt voor alle steun, begrip en niet te vergeten de ontspanning tijdens
de afgelopen periode. Vooral ook voor het lange wachten totdat ik eindelijk eens uitgeleerd
ben.
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